(54) Title: INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS

(57) Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS

BACKGROUND OF THE INVENTION

[0001] Vaccines against various and evolving strains of influenza are important from a community health standpoint, as well as commercially, since each year numerous individuals are infected with different strains and types of influenza virus. Infants, the elderly, those without adequate health care and immuno-compromised persons are at special risk of death from such infections. Compounding the problem of influenza infections is that novel influenza strains evolve readily and can spread amongst various species, thereby necessitating the continuous production of new vaccines.

[0002] Numerous vaccines capable of producing a protective immune response specific for such different and influenza viruses/virus strains have been produced for over 50 years and include whole virus vaccines, split virus vaccines, surface antigen vaccines and live attenuated virus vaccines. However, while appropriate formulations of any of these vaccine types are capable of producing a systemic immune response, live attenuated virus vaccines have the advantage of also being able to stimulate local mucosal immunity in the respiratory tract. Considerable work in the production of influenza viruses, and fragments thereof, for production of vaccines has been done by the present inventors and co-workers; see, e.g., U.S. Application Nos. 60/420,708, filed October 23, 2002; 60/574,117, filed May 24, 2004; 10/423,828, filed April 25, 2003; 60/578,962, filed June 12, 2004; and 10/870,690 filed June 16, 2004, the disclosure of which is incorporated by reference herein.

[0003] Because of the continual emergence (or re-emergence) of different influenza strains, new influenza vaccines are continually desired. Such vaccines typically are created using antigenic moieties of the newly emergent virus strains, thus, polypeptides and polynucleotides of novel, newly emergent, or newly re-emergent virus strains (especially sequences of antigenic genes) are highly desirable.

[0004] The present invention provides new and/or newly isolated influenza hemagglutinin and neuraminidase variants that are capable of use in production of numerous types of vaccines as well as in research, diagnostics, etc. Numerous other benefits will become apparent upon review of the following.
SUMMARY OF THE INVENTION

In some aspects herein, the invention comprises an isolated or recombinant polypeptide that is selected from: the polypeptides encoded by any one of the sequences of SEQ ID NO:1 through SEQ ID NO:10, any one of the polypeptides encoded by SEQ ID NO:1 through SEQ ID NO:10; any one of the polypeptides of SEQ ID NO:11 through SEQ ID NO:20; alternative (e.g., the mature form without the signal peptide, or without the 5' and 3' sequences outside of the open reading frame, or the sequences as expressed on the surface of a virus (e.g., influenza)) forms of the polypeptide of SEQ ID NO:11-20; any polypeptide that is encoded by a polynucleotide sequence which hybridizes under highly stringent conditions over substantially the entire length of a polynucleotide sequence of SEQ ID NO:1 through SEQ ID NO:10; any polypeptide that is encoded by a polynucleotide sequence which hybridizes under highly stringent conditions to a polynucleotide sequence of SEQ ID NO:1 through SEQ ID NO:10; and, a fragment of any of the above wherein the sequence comprises a hemagglutinin or neuraminidase polypeptide, or a fragment of a hemagglutinin or neuraminidase polypeptide, preferably where the fragments generate an antibody that specifically binds a full length polypeptide of the invention. In various embodiments, the isolated or recombinant polypeptides of the invention are substantially identical to about 300 contiguous amino acid residues of any of the above polypeptides. In yet other embodiments, the invention comprises isolated or recombinant polypeptides, that comprise an amino acid sequence that is substantially identical over at least about 350 amino acids; over at least about 400 amino acids; over at least about 450 amino acids; over at least about 500 amino acids; over at least about 502 amino acids; over at least about 550 amino acids; over at least about 559 amino acids; over at least about 565 amino acids; or over at least about 566 amino acids contiguous of any of the above polypeptides. In some embodiments, the polypeptide sequence (e.g., as listed in the sequence listing herein) comprises less than 565, 559, etc. amino acids. In such embodiments, the shorter listed polypeptides optionally comprise less than 565, 559, etc. amino acids. In yet other embodiments, the polypeptides of the invention optionally comprise fusion proteins, proteins with a leader sequence, a precursor polypeptide, proteins with a secretion signal or
a localization signal, or proteins with an epitope tag, an E-tag, or a His epitope tag. In still other embodiments, the invention comprises a polypeptide comprising a sequence having at least 85%, at least 90%, at least 93%, at least 95%, at least 98%, at least 98.5%, at least 99%, at least 99.2%, at least 99.4%, at least 99.6%, at least 99.8%, or at least 99.9% sequence identity to at least one polypeptide listed above. The sequences of the invention are also shown in Appendix 1 and in the sequence listings herein. The hemagglutinin sequences of the invention can comprise both those sequences with unmodified and modified polybasic cleavage sites (thereby allowing growth of the viruses in eggs). The hemagglutinin polypeptide sequences of SEQ ID NOS:11-20 comprise the endogenous amino terminal signal peptide sequences, however, the hemagglutinin polypeptide sequences of the invention also include the mature (amino terminal signal peptide cleaved) form of the hemagglutinin polypeptides. The cleavage sites of any hemagglutinin polypeptide sequence of any influenza strain can be routinely measured or predicted using any number of methods in the art.

[0006] In other aspects, the invention comprises a composition with one or more polypeptide listed above, or fragments thereof. The invention also includes polypeptides that are specifically bound by a polyclonal antiserum raised against at least 1 antigen that comprises at least one amino acid sequence described above, or a fragment thereof. Such antibodies specific for the polypeptides described above are also features of the invention. The polypeptides of the invention are optionally immunogenic.

[0007] The invention also encompasses immunogenic compositions comprising an immunologically effective amount of one or more of any of the polypeptides described above as well as methods for stimulating the immune system of an individual to produce a protective immune response against influenza virus by administering to the individual an immunologically effective amount of any of the above polypeptides in a physiologically acceptable carrier.

[0008] Additionally, the invention includes recombinant influenza virus that comprises one or more of the polypeptides or polynucleotides above, in addition to immunogenic compositions comprising an immunologically effective amount of such recombinant influenza virus. Methods for stimulating the immune system of an individual to produce a protective immune response against influenza virus, through administering an
immunologically effective amount of such recombinant influenza virus in a physiologically acceptable carrier are also part of the invention.

[0009] In other aspects, the invention comprises an isolated or recombinant nucleic acid that is selected from: any one of the polynucleotide sequences SEQ ID NO:1 through SEQ ID NO:10 (or complementary sequences thereof), any one of the polynucleotide sequences encoding a polypeptide of SEQ ID NO:11 through SEQ ID NO:20 (or complementary polynucleotide sequences thereof), a polynucleotide sequence which hybridizes under highly stringent conditions over substantially the entire length of any of the above polynucleotide sequences, and a polynucleotide sequence comprising all or a fragment of any of such polynucleotide sequences wherein the sequence preferably encodes a hemagglutinin or neuraminidase polypeptide or a fragment of a hemagglutinin or neuraminidase polypeptide. The invention also includes an isolated or recombinant nucleic acid that encodes an amino acid sequence which is substantially identical over at least about 300 amino acids of any of the above nucleic acids, or over at least about 350 amino acids; over at least about 400 amino acids; over at least about 450 amino acids; over at least about 500 amino acids; over at least about 502 amino acids; over at least about 550 amino acids; over at least about 559 amino acids; over at least about 565 amino acids; or over at least about 566 amino acids of any of the above nucleic acids. Again, in situations wherein the amino acid is less than, e.g., 566, 565, 559, etc. in length (e.g., see, Sequence Listing) then it should be understood that the length is optionally less than 566, 565, 559, etc. The invention also includes any of the above nucleic acids that comprise a hemagglutinin or neuraminidase polypeptide, or one or more fragments of one or more hemagglutinin or neuraminidase polypeptide. Other aspects of the invention include isolated or recombinant nucleic acids that encode a polypeptide (optionally a hemagglutinin or neuraminidase polypeptide) whose sequence has at least 98% identity, at least 98.5% identity, at least 99% identity, at least 99.2% identity, at least 99.4% identity, at least 99.6% identity, at least 99.8% identity, or at least 99.9% identity to at least one of the above described polynucleotides. The invention also includes isolated or recombinant nucleic acids encoding a polypeptide of hemagglutinin or neuraminidase produced by mutating or recombining one or more above described polynucleotide sequences. The polynucleotide sequences of the invention can optionally comprise one or more of, e.g., a leader sequence,
a precursor sequence, or an epitope tag sequence or the like, and can optionally encode a
fusion protein (e.g., with one or more additional nucleic acid sequences).

In yet other embodiments, the invention comprises a composition of matter
having two or more above described nucleic acids (e.g., a library comprising at least about
2, 5, 10, 50 or more nucleic acids). Such compositions can optionally be produced by
cleaving one or more above described nucleic acid (e.g., mechanically, chemically,
enzymatically with a restriction endonuclease/RNAse/DNAse, etc.). Other compositions of
the invention include, e.g., compositions produced by incubating one or more above
described nucleic acid in the presence of deoxyribonucleotide triphosphates and a
thermostable nucleic acid polymerase.

The invention also encompasses cells comprising at least one of the above
described nucleic acids, or a cleaved or amplified fragment or product thereof. Such cells
can optionally express a polypeptide encoded by such nucleic acid. Other embodiments of
the invention include vectors (e.g., plasmids, cosmids, phage, viruses, virus fragments, etc.)
comprising any of above described nucleic acids. Such vectors can optionally comprise an
expression vector. Preferred expression vectors of the invention include, but are not limited
to, vectors comprising pol I promoter and terminator sequences or vectors using both the pol
I and pol II promoters “the polI/polII promoter system” (e.g., Zobel et al., Nucl. Acids Res.
96:9345; Fodor et al., J. Virol. 1999, 73:9679; and US20030035814). Cells transduced by
such vectors are also within the current invention.

In some embodiments, the invention encompasses a virus (e.g., an influenza
virus) comprising one or more above described nucleic acids (e.g., encoding hemagglutinin
and/or neuraminidase), or one or more fragments thereof. Immunogenic compositions
comprising such virus are also part of the current invention. Such viruses can comprises a
reassortment virus such as a 6:2 reassortment virus (e.g., comprising 6 gene encoding
regions from one or more donor virus and 2 gene encoding regions from one or more above
described nucleotide sequence (or one or more fragment thereof) which can optionally
comprise hemagglutinin and/or neuraminidase). Reassortment viruses (optionally live
viruses) of the invention can include donor viruses that are one or more of, e.g., cold-
sensitive, cold-adapted, or an attenuated. For example, reassortment viruses can comprise
e.g., A/Ann Arbor/6/60, PR8, etc. Reassortment viruses of the invention may alternatively
exclude A/Ann Arbor/6/60. One preferred embodiment of the invention is a reassortant influenza virus, wherein the virus is a 6:2 reassortment influenza virus and comprises 6 gene encoding regions from A/Ann Arbor/6/60 and 2 gene encoding regions that encode a polypeptide selected from the group consisting of: the polypeptides of SEQ ID NOS:11-20.

In an alternative embodiment, a reassortant influenza virus of the invention includes a 6:2 reassortment influenza virus, wherein said virus comprises 6 gene encoding regions from one or more donor viruses other than A/Ann Arbor/6/60 and 2 gene encoding regions that encode a polypeptide selected from the group consisting of: the polypeptides of SEQ ID NOS:11-20. In another alternative embodiment, a reassortant influenza virus of the invention includes a 6:2 reassortment influenza virus, wherein said virus comprises 6 gene encoding regions from one or more donor viruses other than A/Ann Arbor/6/60 and 2 gene encoding regions, wherein the 2 gene encoding regions are HA or NA polypeptides from any pandemic influenza strain. Methods of producing recombinant influenza virus through culturing a host cell harboring an influenza virus in a suitable culture medium under conditions permitting expression of nucleic acid and, isolating the recombinant influenza virus from one or more of the host cell or the medium are also part of the invention.

[0013] In other embodiments herein, the invention comprises immunogenic compositions having an immunologically effective amount of any of the above described recombinant influenza virus. Other embodiments include methods for stimulating the immune system of an individual to produce a protective immune response against influenza virus by administering to the individual an immunologically effective amount of any of the recombinant influenza virus described above (optionally in a physiologically effective carrier).

[0014] Other aspects of the invention include methods of producing an isolated or recombinant polypeptide by culturing any host cell above, in a suitable culture medium under conditions permitting expression of nucleic acid and, isolating the polypeptide from one or more of the host cells or the medium in which is the cells are grown.

[0015] Immunogenic compositions are also features of the invention. For example, immunogenic compositions comprising one or more of any of the polypeptides and/or nucleic acids described above and, optionally, an excipient such as a pharmaceutically acceptable excipient or one or more pharmaceutically acceptable administration component. Immunogenic compositions of the invention can also comprise any one or more above
described virus as well (e.g., along with one or more pharmaceutically acceptable administration component).

[0016] Methods of producing immunogenic responses in a subject through administration of an effective amount of any of the above viruses (or immunogenic compositions) to a subject are also within the current invention. Additionally, methods of prophylactic or therapeutic treatment of a viral infection (e.g., viral influenza) in a subject through administration of any one or more above described virus (or immunogenic compositions) in an amount effective to produce an immunogenic response against the viral infection are also part of the current invention. Subjects for such treatment can include mammals (e.g., humans). Such methods can also comprise in vivo administration to the subject as well as in vitro or ex vivo administration to one or more cells of the subject. Additionally, such methods can also comprise administration of a composition of the virus and a pharmaceutically acceptable excipient that are administered to the subject in an amount effective to prophylactically or therapeutically treat the viral infection.

[0017] In other aspects the invention includes compositions of matter comprising nucleic acid sequences encoding hemagglutinin and/or neuraminidase polypeptides of one or more pandemic influenza strain and nucleic acid sequences encoding one or more polypeptide of A/Ann Arbor/6/60. Additionally, the invention includes compositions of matter comprising nucleic acid sequences encoding hemagglutinin and/or neuraminidase polypeptides of one or more pandemic influenza strain and nucleic acid sequences encoding one or more polypeptide of PR8 or A/Ann Arbor/6/60. Such sequences can include those listed in the Sequence Listing herein. Additionally, preferred embodiments of the invention include compositions of matter comprising sequences encoding hemagglutinin and/or neuraminidase of one or more pandemic influenza strain and nucleic acid sequences encoding a selected backbone strain in a 6:2 reassortment. Such compositions preferably include sequences encoding the hemagglutinin and neuraminidase selected from the Sequence Listing herein and a backbone strain, wherein the backbone strain is PR8 or A/Ann Arbor/6/60. The invention also includes such compositions as described above wherein the hemagglutinin comprises a modified polybasic cleavage site. The invention also includes live attenuated influenza vaccine comprising such above compositions.
[0018] These and other objects and features of the invention will become more fully apparent when the following detailed description is read in conjunction with the accompanying figures and appendix.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1: Shows modifications engineered into the HA gene of VN/1203/2004 to remove the polybasic cleavage site.

[0020] Figure 2: Displays results showing that intranasally administered H5N1 ca reassortant viruses do not replicate in chickens.

[0021] Figure 3: Illustrates that the H5N1/AA ca vaccine candidates are not lethal to mice.

[0022] Figure 4: Illustrates that the 1997 and 2004 H5N1 ca reassortant viruses are restricted in replication in mice.

[0023] Figure 5: Illustrates that the reassortant H5N1/AA ca influenza viruses are restricted in replication in lungs of mice.

[0024] Figure 6: Shows the serum HA1 Ab titers elicited in mice following a single i.n. dose of vaccine.

[0025] Figure 7: Shows serum neutralizing Ab titers elicited in mice following a single i.n. dose of vaccine.

[0026] Figure 8: Illustrates that H5N1 ca reassortant viruses protect mice from lethal challenges with 50, 500 or 5000 LD_{50} of wild-type H5N1 viruses.

[0027] Figure 9: Illustrates the efficacy of protection from pulmonary replication of homologous and heterologous H5N1 challenge viruses in mice.

[0028] Figure 10: Illustrates the efficacy of protection from replication of homologous and heterologous H5N1 challenge viruses in the upper respiratory tract of mice.

[0029] Figure 11: Illustrates the efficacy of protection conferred by 2004 H5N1 ca vaccine against high dose (10_{5}TCID_{50}) challenge with homologous or heterologous H5N1 wt viruses in mice.
Figure 12: Illustrates the efficacy of protection conferred by 1997 and 2003 H5N1 ca vaccines against high dose (10⁵TCID₅₀) challenges with homologous or heterologous H5N1 wild-type viruses in mice.

Figure 13: Illustrates the efficacy of protection conferred by 2004 H5N1 ca vaccine against low or high doses of homologous H5N1 wild-type virus challenges in mice.

DETAILED DESCRIPTION

The present invention includes polypeptide and polynucleotide sequences of influenza hemagglutinin and neuraminidase as well as vectors, compositions and the like comprising such sequences and methods of their use. Additional features of the invention are described in more detail herein.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. The following definitions supplement those in the art and are directed to the current application and are not necessarily to be imputed to any related or unrelated case, e.g., to any commonly owned patent or application. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the preferred materials and methods are described herein. Accordingly, the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a virus” includes a plurality of viruses; reference to a “host cell” includes mixtures of host cells, and the like.

An “amino acid sequence” is a polymer of amino acid residues (a protein, polypeptide, etc.) or a character string representing an amino acid polymer, depending on context.
The terms “nucleic acid,” “polynucleotide,” “polynucleotide sequence” and “nucleic acid sequence” refer to single-stranded or double-stranded deoxyribonucleotide or ribonucleotide polymers, chimeras or analogues thereof, or a character string representing such, depending on context. As used herein, the term optionally includes polymers of analogs of naturally occurring nucleotides having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g., peptide nucleic acids). Unless otherwise indicated, a particular nucleic acid sequence of this invention optionally encompasses complementary sequences in addition to the sequence explicitly indicated. From any specified polynucleotide sequence, either the given nucleic acid or the complementary polynucleotide sequence (e.g., the complementary nucleic acid) can be determined.

The term “nucleic acid” or “polynucleotide” also encompasses any physical string of monomer units that can be corresponded to a string of nucleotides, including a polymer of nucleotides (e.g., a typical DNA or RNA polymer), PNAs, modified oligonucleotides (e.g., oligonucleotides comprising bases that are not typical to biological RNA or DNA in solution, such as 2′-O-methylated oligonucleotides), and the like. A nucleic acid can be e.g., single-stranded or double-stranded.

A “subsequence” is any portion of an entire sequence, up to and including the complete sequence. Typically, a subsequence comprises less than the full-length sequence. A “unique subsequence” is a subsequence that is not found in any previously determined influenza polynucleotide or polypeptide sequence.

The term “variant” with respect to a polypeptide refers to an amino acid sequence that is altered by one or more amino acids with respect to a reference sequence. The variant can have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. Alternatively, a variant can have “nonconservative” changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variation can also include amino acid deletion or insertion, or both. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without eliminating biological or immunological activity can be found using computer programs well known in the art, for example, DNASTAR software. Examples of conservative substitutions are also described herein.
The term “gene” is used broadly to refer to any nucleic acid associated with a biological function. Thus, genes include coding sequences and/or the regulatory sequences required for their expression. The term “gene” applies to a specific genomic sequence, as well as to a cDNA or an mRNA encoded by that genomic sequence.

Genes also include non-expressed nucleic acid segments that, for example, form recognition sequences for other proteins. Non-expressed regulatory sequences include “promoters” and “enhancers,” to which regulatory proteins such as transcription factors bind, resulting in transcription of adjacent or nearby sequences. A “tissue specific” promoter or enhancer is one that regulates transcription in a specific tissue type or cell type, or types.

“Expression of a gene” or “expression of a nucleic acid” means transcription of DNA into RNA (optionally including modification of the RNA, e.g., splicing), translation of RNA into a polypeptide (possibly including subsequent modification of the polypeptide, e.g., post-translational modification), or both transcription and translation, as indicated by the context.

An “open reading frame” or “ORF” is a possible translational reading frame of DNA or RNA (e.g., of a gene), which is capable of being translated into a polypeptide. That is, the reading frame is not interrupted by stop codons. However, it should be noted that the term ORF does not necessarily indicate that the polynucleotide is, in fact, translated into a polypeptide.

The term “vector” refers to the means by which a nucleic acid can be propagated and/or transferred between organisms, cells, or cellular components. Vectors include plasmids, viruses, bacteriophages, pro-viruses, phagemids, transposons, artificial chromosomes, and the like, that replicate autonomously or can integrate into a chromosome of a host cell. A vector can also be a naked RNA polynucleotide, a naked DNA polynucleotide, a polynucleotide composed of both DNA and RNA within the same strand, a poly-lysine-conjugated DNA or RNA, a peptide-conjugated DNA or RNA, a liposome-conjugated DNA, or the like, that is not autonomously replicating. In many, but not all, common embodiments, the vectors of the present invention are plasmids.

An “expression vector” is a vector, such as a plasmid that is capable of promoting expression, as well as replication of a nucleic acid incorporated therein.
Typically, the nucleic acid to be expressed is "operably linked" to a promoter and/or enhancer, and is subject to transcription regulatory control by the promoter and/or enhancer.

[0046] A "bi-directional expression vector" is characterized by two alternative promoters oriented in the opposite direction relative to a nucleic acid situated between the two promoters, such that expression can be initiated in both orientations resulting in, e.g., transcription of both plus (+) or sense strand, and negative (-) or antisense strand RNAs.

[0047] A "polypeptide" is a polymer comprising two or more amino acid residues (e.g., a peptide or a protein). The polymer can optionally comprise modifications such as glycosylation or the like. The amino acid residues of the polypeptide can be natural or non-natural and can be unsubstituted, unmodified, substituted or modified.

[0048] In the context of the invention, the term "isolated" refers to a biological material, such as a virus, a nucleic acid or a protein, which is substantially free from components that normally accompany or interact with it in its naturally occurring environment. The isolated biological material optionally comprises additional material not found with the biological material in its natural environment, e.g., a cell or wild-type virus. For example, if the material is in its natural environment, such as a cell, the material can have been placed at a location in the cell (e.g., genome or genetic element) not native to such material found in that environment. For example, a naturally occurring nucleic acid (e.g., a coding sequence, a promoter, an enhancer, etc.) becomes isolated if it is introduced by non-naturally occurring means to a locus of the genome (e.g., a vector, such as a plasmid or virus vector, or amplicon) not native to that nucleic acid. Such nucleic acids are also referred to as "heterologous" nucleic acids. An isolated virus, for example, is in an environment (e.g., a cell culture system, or purified from cell culture) other than the native environment of wild-type virus (e.g., the nasopharynx of an infected individual).

[0049] The term "chimeric" or "chimera," when referring to a virus, indicates that the virus includes genetic and/or polypeptide components derived from more than one parental viral strain or source. Similarly, the term "chimeric" or "chimera," when referring to a viral protein, indicates that the protein includes polypeptide components (i.e., amino acid subsequences) derived from more than one parental viral strain or source.

[0050] The term "recombinant" indicates that the material (e.g., a nucleic acid or protein) has been artificially or synthetically (non-naturally) altered by human intervention.
The alteration can be performed on the material within, or removed from, its natural environment or state. Specifically, e.g., an influenza virus is recombinant when it is produced by the expression of a recombinant nucleic acid. For example, a “recombinant nucleic acid” is one that is made by recombining nucleic acids, e.g., during cloning, DNA shuffling or other procedures, or by chemical or other mutagenesis; a “recombinant polypeptide” or “recombinant protein” is a polypeptide or protein which is produced by expression of a recombinant nucleic acid; and a “recombinant virus”, e.g., a recombinant influenza virus, is produced by the expression of a recombinant nucleic acid.

[0051] The term “reassortant,” when referring to a virus, indicates that the virus includes genetic and/or polypeptide components derived from more than one parental viral strain or source. For example, a 7:1 reassortant includes 7 viral genomic segments (or gene segments) derived from a first parental virus, and a single complementary viral genomic segment, e.g., encoding a hemagglutinin or neuraminidase of the invention. A 6:2 reassortant includes 6 genomic segments, most commonly the 6 internal genes from a first parental virus, and two complementary segments, e.g., hemagglutinin and neuraminidase, from a different parental virus.

[0052] The term “introduced” when referring to a heterologous or isolated nucleic acid refers to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid can be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA). The term includes such methods as “infection,” “transfection,” “transformation” and “transduction.” In the context of the invention a variety of methods can be employed to introduce nucleic acids into cells, including electroporation, calcium phosphate precipitation, lipid mediated transfection (lipofection), etc.

[0053] The term “host cell” means a cell that contains a heterologous nucleic acid, such as a vector, and supports the replication and/or expression of the nucleic acid. Host cells can be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, avian or mammalian cells, including human cells. Exemplary host cells can include, e.g., Vero (African green monkey kidney) cells, BHK (baby hamster kidney) cells, primary chick kidney (PCK) cells, Madin-Darby Canine Kidney (MDCK) cells, Madin-
Darby Bovine Kidney (MDBK) cells, 293 cells (e.g., 293T cells), and COS cells (e.g., COS1, COS7 cells), etc.

[0054] An "immunologically effective amount" of influenza virus is an amount sufficient to enhance an individual's (e.g., a human's) own immune response against a subsequent exposure to influenza virus. Levels of induced immunity can be monitored, e.g., by measuring amounts of neutralizing secretory and/or serum antibodies, e.g., by plaque neutralization, complement fixation, enzyme-linked immunosorbent, or microneutralization assay.

[0055] A "protective immune response" against influenza virus refers to an immune response exhibited by an individual (e.g., a human) that is protective against disease when the individual is subsequently exposed to and/or infected with such influenza virus. In some instances, the influenza virus (e.g., naturally circulating) can still cause infection, but it cannot cause a serious infection. Typically, the protective immune response results in detectable levels of host engendered serum and secretory antibodies that are capable of neutralizing virus of the same strain and/or subgroup (and possibly also of a different, non-vaccine strain and/or subgroup) in vitro and in vivo.

[0056] As used herein, an "antibody" is a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively. Antibodies exist as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab')2, a dimer of Fab which itself is a light chain joined to VH-CH1 by
a disulfide bond. The F(ab')2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab')2 dimer into a Fab' monomer. The Fab' monomer is essentially a Fab with part of the hinge region (see, Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1999), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, includes antibodies or fragments either produced by the modification of whole antibodies or synthesized de novo using recombinant DNA methodologies. Antibodies include, e.g., polyclonal antibodies, monoclonal antibodies, multiple or single chain antibodies, including single chain Fv (sFv or scFv) antibodies in which a variable heavy and a variable light chain are joined together (directly or through a peptide linker) to form a continuous polypeptide, and humanized or chimeric antibodies.

**INFLUENZA VIRUS**

The polypeptides and polynucleotides of the invention, e.g., SEQ ID NO: 1-20, are variants of influenza HA and NA sequences. In general, influenza viruses are made up of an internal ribonucleoprotein core containing a segmented single-stranded RNA genome and an outer lipoprotein envelope lined by a matrix protein. The genome of influenza viruses is composed of eight segments of linear (-) strand ribonucleic acid (RNA), encoding the immunogenic hemagglutinin (HA) and neuraminidase (NA) proteins, and six internal core polypeptides: the nucleocapsid nucleoprotein (NP); matrix proteins (M); non-structural proteins (NS); and 3 RNA polymerase (PA, PB1, PB2) proteins. During replication, the genomic viral RNA is transcribed into (+) strand messenger RNA and (-) strand genomic cRNA in the nucleus of the host cell. Each of the eight genomic segments is packaged into ribonucleoprotein complexes that contain, in addition to the RNA, NP and a polymerase complex (PB1, PB2, and PA).

Influenza is commonly grouped into influenza A and influenza B categories. Influenza A and influenza B viruses each contain eight segments of single stranded RNA with negative polarity. The influenza A genome encodes eleven polypeptides. Segments 1-3 encode three polypeptides, making up a RNA-dependent RNA polymerase. Segment 1 encodes the polymerase complex protein PB2. The remaining polymerase proteins PB1 and
PA are encoded by segment 2 and segment 3, respectively. In addition, segment 1 of some influenza strains encodes a small protein, PB1-F2, produced from an alternative reading frame within the PB1 coding region. Segment 4 encodes the hemagglutinin (HA) surface glycoprotein involved in cell attachment and entry during infection. Segment 5 encodes the nucleocapsid nucleoprotein (NP) polypeptide, the major structural component associated with viral RNA. Segment 6 encodes a neuraminidase (NA) envelope glycoprotein. Segment 7 encodes two matrix proteins, designated M1 and M2, which are translated from differentially spliced mRNAs. Segment 8 encodes NS1 and NS2, two nonstructural proteins, which are translated from alternatively spliced mRNA variants. The eight genome segments of influenza B encode 11 proteins. The three largest genes code for components of the RNA polymerase, PB1, PB2 and PA. Segment 4 encodes the HA protein. Segment 5 encodes NP. Segment 6 encodes the NA protein and the NB protein. Both proteins, NB and NA, are translated from overlapping reading frames of a bicistronic mRNA. Segment 7 of influenza B also encodes two proteins: M1 and BM2. The smallest segment encodes two products: NS1 is translated from the full length RNA, while NS2 is translated from a spliced mRNA variant.

INFLUENZA VIRUS VACCINES

The sequences, compositions and methods herein are primarily, but not solely, concerned with production of influenza viruses for vaccines. Historically, influenza virus vaccines have primarily been produced in embryonated hen eggs using strains of virus selected or based on empirical predictions of relevant strains. More recently, reassortant viruses have been produced that incorporate selected hemagglutinin and/or neuraminidase antigens in the context of an approved attenuated, temperature sensitive master strain. Following culture of the virus through multiple passages in hen eggs, influenza viruses are recovered and, optionally, inactivated, e.g., using formaldehyde and/or β-propiolactone (or alternatively used in live attenuated vaccines). Thus, it will be appreciated that HA and NA sequences (e.g., SEQ ID NO: 1-20) are quite useful in constructing influenza vaccines. The current invention includes viruses/vaccines comprising HA and/or NA sequences of pandemic influenza strains (including wherein the HA sequences comprise modified polybasic cleavage sites such as the modifications described herein); and including wherein the viruses/vaccines comprise a ca backbone such as A/AA/6/60 or the backbone of PR8.
Attempts at producing recombinant and reassortant vaccines in cell culture have been hampered by the inability of some of the strains approved for vaccine production to grow efficiently under standard cell culture conditions. However, prior work by the inventors and their coworkers provided a vector system, and methods for producing recombinant and reassortant viruses in culture, thus, making it possible to rapidly produce vaccines corresponding to one or many selected antigenic strains of virus, e.g., either A or B strains, various subtypes or substrains, etc., e.g., comprising the HA and/or NA sequences herein. See, Multi-Plasmid System for the production of Influenza virus, U.S. Application No. 60/420,708, filed October 23, 2002, U.S. Application No. 10/423,828, filed April 25, 2003 and U.S. Application 60/574,117 filed May 24, 2004. Typically, the cultures are maintained in a system, such as a cell culture incubator, under controlled humidity and CO₂, at constant temperature using a temperature regulator, such as a thermostat to insure that the temperature does not exceed 35 °C. Reassortant influenza viruses can be readily obtained by introducing a subset of vectors corresponding to genomic segments of a master influenza virus, in combination with complementary segments derived from strains of interest (e.g., HA and/or NA antigenic variants herein). Typically, the master strains are selected on the basis of desirable properties relevant to vaccine administration. For example, for vaccine production, e.g., for production of a live attenuated vaccine, the master donor virus strain may be selected for an attenuated phenotype, cold adaptation and/or temperature sensitivity. As explained elsewhere herein and, e.g., in U.S. Patent Application No. 10/423,828, etc., various embodiments of the invention utilize A/Ann Arbor (AA)/6/60 influenza strain as a “backbone” upon which to add HA and/or NA genes (e.g., such as those sequences listed herein, etc.) to create desired reassortant viruses. Thus, for example, in a 6:2 reassortant, 2 genes (i.e., NA and HA) would be from the influenza strain(s) against which an immunogenic reaction is desired, while the other 6 genes would be from the Ann Arbor strain, or other backbone strain, etc. The Ann Arbor virus is useful for its cold adapted, attenuated, temperature sensitive attributes. Of course, it will be appreciated that the HA and NA sequences herein are capable of reassortment with a number of other virus genes or virus types (e.g., a number of different “backbones” such as PR8, etc., containing the other influenza genes present in a reassortant, namely, the non-HA and non-NA genes

Various embodiments herein can comprise live attenuated vaccines, having the HA and/or NA sequences herein, for pandemic influenza. Such vaccines typically
comprise, e.g., the HA and/or NA sequences of SEQ ID NO: 11-20, or their corresponding nucleotides of SEQ ID NO: 1-10. One problem arising from growth of vaccine virus strains (e.g., reassortants) in eggs is that avian strains (which can be involved in pandemics) can kill the eggs in which the vaccines are to be produced and are, thus, hard to manipulate, produce, etc. through use of traditional (non-plasmid rescue) reassortant production. Such avian strains are of interest since evidence indicates they can result in influenza in humans and possible pandemics. Thus, use of plasmid-rescue systems to create/manipulate influenza reassortants with pandemic strains such as various avian sequences (e.g., the HA and NA sequences herein) are quite desirable and are features of the invention. It will be appreciated, however, that the current sequences are also capable of use with non-plasmid or traditional systems.

Aquatic birds (among others) can be infected by influenza A viruses of 15 hemagglutinin (HA) and 9 neuraminidase (NA) subtypes. Such birds can serve as a reservoir from which novel influenza subtypes can be introduced into human populations and cause pandemics. The observation that avian H7N7 influenza A viruses infected humans in The Netherlands in 2003 and avian H5N1 and H9N2 viruses infected humans in Hong Kong and China earlier, raise concerns that these (and other) subtypes have the potential to cause pandemics. Thus, vaccines are needed to prevent human infections with avian influenza A viruses. Live, attenuated influenza A virus vaccines against human influenza viruses were recently licensed in the United States. See above. Such vaccines are reassortant H1N1 and H3N2 viruses in which the internal protein genes of A/Ann Arbor (AA)/6/60 (H2N2) cold adapted (ca) virus confer the cold adapted, attenuation and temperature sensitive phenotypes of the AA ca virus on the reassortant viruses (i.e., the ones having the hemagglutinin and neuraminidase genes from the non-Ann Arbor strain).

Classical genetic reassortment and plasmid-based reverse genetics techniques have been applied to generate reassortant viruses that contain the hemagglutinin and neuraminidase genes from avian influenza A viruses (H4-H14 subtypes) and six internal gene segments from the AA ca virus. Such reassortant viruses are features of the invention. See the HA and NA gene sequences below. These viruses bear biological properties that are desirable in candidate vaccines because the phenotypes associated with the AA ca virus are present in the reassortant viruses. The generation and evaluation of these reassortant viruses as seed viruses for vaccines are important steps in pandemic preparedness. It is contemplated that
clinical trials can establish the safety, infectivity and immunogenicity of such live attenuated pandemic vaccines. Other embodiments of the invention include reassortant viruses (e.g., those used in vaccines) comprising pandemic antigenic genes HA and/or NA from, e.g., avian, porcine, etc., pandemic virus strains in addition to those listed herein, to produce pandemic vaccines which are created through plasmid-rescue reassortment (e.g., reassortment with A/Ann Arbor 6/60 (i.e., A/AA/6/60), PR8, etc. Methods of construction and use of such viruses and vaccines are also included. “Pandemic virus strains” as used herein is defined as an influenza strain A virus subtype that it is not circulating in the human population, that is declared to be a pandemic strain by the Centers for Disease Control or the World Health Organization or generally acknowledged as such within the scientific community.

[0063] In various embodiments herein, the antigenic sequences (e.g., the HA sequences) as well as viruses and vaccines from such viruses comprise modified polybasic cleavage sites. Some highly pathogenic avian pandemic influenza strains comprise multiple basic amino acid cleavage sites within hemagglutinin sequences. See, e.g., Li et al., J. of Infectious Diseases, 179:1132-8, 1999. Such cleavage sites, in typical embodiments herein, are, e.g., modified or altered in their sequences in comparison to the wild-type sequences from which the current sequences are derived (e.g., to disable the cleavage or reduce the cleavage there, etc.). Such modifications/alterations can be different in different strains due to the various sequences of the cleavage sites in the wild-type sequences. For example, 4 polybasic residues (RRKK) at 326-329 of mature H5 are typically removed in sequences herein (as compared to wt). See sequence listing and Figure 1. In various embodiments, the polybasic cleavage sites can be modified in a number of ways (all of which are contained within the invention). For example, the polybasic cleavage site can be removed one amino acid at a time (e.g., one R removed, two Rs removed, RRK removed, or RRKK removed). Additionally, the amino acid residue directly upstream of the cleavage site can also be removed or altered (e.g., from an R to a T, etc.); also, the nucleotides encoding the amino acid residue directly after the cleavage site can also be modified. See, e.g., Figure 1 for an illustration of cleavage site modification. In addition, hemagglutinin polypeptide sequences of influenza virus comprise amino terminal signal peptide sequences, thus, the hemagglutinin polypeptide sequences of the invention include both the mature (amino terminal signal peptide cleaved) form of the hemagglutinin polypeptides and the pre-cleaved
form of hemagglutinin. The cleavage sites of any hemagglutinin polypeptide sequence of any influenza strain can be routinely measured or predicted using any number of methods in the art.

[0064] The terms “temperature sensitive,” “cold adapted” and “attenuated” as applied to viruses (typically used as vaccines or for vaccine production) which optionally encompass the current sequences, are well known in the art. For example, the term “temperature sensitive” (ts) indicates, e.g., that the virus exhibits a 100 fold or greater reduction in titer at 39°C relative to 33°C for influenza A strains, or that the virus exhibits a 100 fold or greater reduction in titer at 37°C relative to 33°C for influenza B strains. The term “cold adapted” (ca) indicates that the virus exhibits growth at 25°C within 100 fold of its growth at 33°C, while the term “attenuated” (att) indicates that the virus replicates in the upper airways of ferrets but is not detectable in their lung tissues, and does not cause influenza-like illness in the animal. It will be understood that viruses with intermediate phenotypes, i.e., viruses exhibiting titer reductions less than 100 fold at 39°C (for A strain viruses) or 37°C (for B strain viruses), or exhibiting growth at 25°C that is more than 100 fold than its growth at 33°C (e.g., within 200 fold, 500 fold, 1000 fold, 10,000 fold less), and/or exhibit reduced growth in the lungs relative to growth in the upper airways of ferrets (i.e., partially attenuated) and/or reduced influenza like illness in the animal, are also useful viruses and can be used in conjunction with the HA and NA sequences herein.

[0065] Again, the HA and NA sequences of the current invention are optionally utilized in such plasmid reassortment vaccines (and/or in other ts, cs, ca, and/or att viruses and vaccines). However, it should be noted that the HA and NA sequences, etc. of the invention are not limited to specific vaccine compositions or production methods, and can, thus, be utilized in substantially any vaccine type or vaccine production method which utilizes strain specific HA and NA antigens (e.g., any of SEQ ID NO: 11-20 or the corresponding nucleotides in SEQ ID NO: 1-10).

FLUMIST™

[0066] As mentioned previously, numerous examples and types of influenza vaccine exist. An exemplary influenza vaccine is Flumist™ which is a live, attenuated vaccine that protects children and adults from influenza illness (Belshe et al. (1998) The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children N Engl J
Med 338:1405-12; Nichol et al. (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial JAMA 282:137-44). In typical, and preferred, embodiments, the methods and compositions of the current invention are preferably adapted to/used with production of FluMist™ vaccine. However, it will be appreciated by those skilled in the art that the sequences, methods, compositions, etc. herein are also adaptable to production of similar or even different viral vaccines.

FluMist™ vaccine strains contain, e.g., HA and NA gene segments derived from the strains (e.g., wild-type strains) to which the vaccine is addressed along with six gene segments, PB1, PB2, PA, NP, M and NS, from a common master donor virus (MDV).

The HA sequences herein, thus, are part of various FluMist™ formulations. The MDV for influenza A strains of FluMist™ (MDV-A), was created by serial passage of the wild-type A/Ann Arbor/6/60 (A/AA/6/60) strain in primary chicken kidney tissue culture at successively lower temperatures (Maassab 1967) Adaptation and growth characteristics of influenza virus at 25 degrees C Nature 213:612-4). MDV-A replicates efficiently at 25°C (ca, cold adapted), but its growth is restricted at 38 and 39°C (ts, temperature sensitive). Additionally, this virus does not replicate in the lungs of infected ferrets (att, attenuation). The ts phenotype is believed to contribute to the attenuation of the vaccine in humans by restricting its replication in all but the coolest regions of the respiratory tract. The stability of this property has been demonstrated in animal models and clinical studies. In contrast to the ts phenotype of influenza strains created by chemical mutagenesis, the ts property of MDV-A does not revert following passage through infected hamsters or in shed isolates from children (for a recent review, see Murphy & Coelingh (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines Viral Immunol 15:295-323).


[0069] Production of such reassorted virus using B strains of influenza is more difficult, however, recent work (see, e.g., Multi-Plasmid System for the Production of Influenza Virus, U.S. Application No. 60/420,708, filed October 23, 2002, U.S. Application No. 10/423,828, filed April 25, 2003, and U.S. Application No. 60/574,117, filed May 24, 2004) has shown an eight plasmid system for the generation of influenza B virus entirely from cloned cDNA. Methods for the production of attenuated live influenza A and B virus suitable for vaccine formulations, such as live virus vaccine formulations useful for intranasal administration were also shown.

[0070] The system and methods described previously are useful for the rapid production in cell culture of recombinant and reassortant influenza A and B viruses, including viruses suitable for use as vaccines, including live attenuated vaccines, such as vaccines suitable for intranasal administration. The sequences (e.g., SEQ ID NO: 1-10 and the corresponding amino acids in SEQ ID NO: 11-20), methods, etc. of the current invention, are optionally used in conjunction with, or in combination with, such previous work involving, e.g., reassorted influenza viruses for vaccine production to produce viruses for vaccines.

METHODS AND COMPOSITIONS FOR PROPHYLACTIC ADMINISTRATION OF VACCINES

[0071] As stated above, alternatively, or in addition to, use in production of FluMist™ vaccine, the current invention can be used in other vaccine formulations. In general, recombinant and reassortant viruses of the invention (e.g., those comprising polynucleotides of SEQ ID NO:1-10 or polypeptides of SEQ ID NO:11-20, or fragments thereof) can be administered prophylactically in an immunologically effective amount and in an appropriate carrier or excipient to stimulate an immune response specific for one or more strains of influenza virus as determined by the HA and/or NA sequence. Typically, the carrier or excipient is a pharmaceutically acceptable carrier or excipient, such as sterile
water, aqueous saline solution, aqueous buffered saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, ethanol, or combinations thereof. The preparation of such solutions insuring sterility, pH, isotonicity, and stability is effected according to protocols established in the art. Generally, a carrier or excipient is selected to minimize allergic and other undesirable effects, and to suit the particular route of administration, e.g., subcutaneous, intramuscular, intranasal, etc.

[0072] A related aspect of the invention provides methods for stimulating the immune system of an individual to produce a protective immune response against influenza virus. In the methods, an immunologically effective amount of a recombinant influenza virus (e.g., comprising an HA and/or NA molecule of the invention), an immunologically effective amount of a polypeptide of the invention, and/or an immunologically effective amount of a nucleic acid of the invention is administered to the individual in a physiologically acceptable carrier.

[0073] Generally, the influenza viruses of the invention are administered in a quantity sufficient to stimulate an immune response specific for one or more strains of influenza virus (i.e., against the HA and/or NA strains of the invention). Preferably, administration of the influenza viruses elicits a protective immune response to such strains. Dosages and methods for eliciting a protective immune response against one or more influenza strains are known to those of skill in the art. See, e.g., USPN 5,922,326; Wright et al., Infect. Immun. 37:397-400 (1982); Kim et al., Pediatrics 52:56-63 (1973); and Wright et al., J. Pediatr. 88:931-936 (1976). For example, influenza viruses are provided in the range of about 1-1000 HI50 (human infectious dose), i.e., about $10^5$ - $10^8$ pfu (plaque forming units) per dose administered. Typically, the dose will be adjusted within this range based on, e.g., age, physical condition, body weight, sex, diet, time of administration, and other clinical factors. The prophylactic vaccine formulation is systemically administered, e.g., by subcutaneous or intramuscular injection using a needle and syringe, or a needle-less injection device. Alternatively, the vaccine formulation is administered intranasally, either by drops, large particle aerosol (greater than about 10 microns), or spray into the upper respiratory tract. While any of the above routes of delivery results in a protective systemic immune response, intranasal administration confers the added benefit of eliciting mucosal immunity at the site of entry of the influenza virus. For intranasal administration, attenuated live virus vaccines are often preferred, e.g., an attenuated, cold adapted and/or
temperature sensitive recombinant or reassortant influenza virus. See above. While stimulation of a protective immune response with a single dose is preferred, additional dosages can be administered, by the same or different route, to achieve the desired prophylactic effect.

Typically, the attenuated recombinant influenza of this invention as used in a vaccine is sufficiently attenuated such that symptoms of infection, or at least symptoms of serious infection, will not occur in most individuals immunized (or otherwise infected) with the attenuated influenza virus. In some instances, the attenuated influenza virus can still be capable of producing symptoms of mild illness (e.g., mild upper respiratory illness) and/or of dissemination to unvaccinated individuals. However, its virulence is sufficiently abrogated such that severe lower respiratory tract infections do not occur in the vaccinated or incidental host.

Alternatively, an immune response can be stimulated by ex vivo or in vivo targeting of dendritic cells with influenza viruses comprising the sequences herein. For example, proliferating dendritic cells are exposed to viruses in a sufficient amount and for a sufficient period of time to permit capture of the influenza antigens by the dendritic cells. The cells are then transferred into a subject to be vaccinated by standard intravenous transplantation methods.

While stimulation of a protective immune response with a single dose is preferred, additional dosages can be administered, by the same or different route, to achieve the desired prophylactic effect. In neonates and infants, for example, multiple administrations may be required to elicit sufficient levels of immunity. Administration can continue at intervals throughout childhood, as necessary to maintain sufficient levels of protection against wild-type influenza infection. Similarly, adults who are particularly susceptible to repeated or serious influenza infection, such as, for example, health care workers, day care workers, family members of young children, the elderly, and individuals with compromised cardiopulmonary function may require multiple immunizations to establish and/or maintain protective immune responses. Levels of induced immunity can be monitored, for example, by measuring amounts of neutralizing secretory and serum antibodies, and dosages adjusted or vaccinations repeated as necessary to elicit and maintain desired levels of protection.
Optionally, the formulation for prophylactic administration of the influenza viruses also contains one or more adjuvants for enhancing the immune response to the influenza antigens. Suitable adjuvants include: complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, bacille Calmette-Guerin (BCG), Corynebacterium parvum, and the synthetic adjuvant QS-21.

If desired, prophylactic vaccine administration of influenza viruses can be performed in conjunction with administration of one or more immunostimulatory molecules. Immunostimulatory molecules include various cytokines, lymphokines and chemokines with immunostimulatory, immunopotentiating, and pro-inflammatory activities, such as interleukins (e.g., IL-1, IL-2, IL-3, IL-4, IL-12, IL-13); growth factors (e.g., granulocyte-macrophage (GM)-colony stimulating factor (CSF)); and other immunostimulatory molecules, such as macrophage inflammatory factor, Flt3 ligand, B7.1; B7.2, etc. The immunostimulatory molecules can be administered in the same formulation as the influenza viruses, or can be administered separately. Either the protein (e.g., an HA and/or NA polypeptide of the invention, e.g., any of SEQ ID NO: 11-20) or an expression vector comprising a nucleic acid (e.g., any of SEQ ID NO: 1-10) encoding the protein can be administered to produce an immunostimulatory effect.

The above described methods are useful for therapeutically and/or prophylactically treating a disease or disorder, typically influenza, by introducing a vector of the invention comprising a heterologous polynucleotide encoding a therapeutically or prophylactically effective HA and/or NA polypeptide (or peptide) or HA and/or NA RNA (e.g., an antisense RNA or ribozyme) into a population of target cells in vitro, ex vivo or in vivo. Typically, the polynucleotide encoding the polypeptide (or peptide), or RNA, of interest is operably linked to appropriate regulatory sequences as described above in the sections entitled "Expression Vectors" and "Additional Expression Elements." Optionally, more than one heterologous coding sequence is incorporated into a single vector or virus. For example, in addition to a polynucleotide encoding a therapeutically or prophylactically active HA and/or NA polypeptide or RNA, the vector can also include additional therapeutic or prophylactic polypeptides, e.g., antigens, co-stimulatory molecules, cytokines, antibodies, etc., and/or markers, and the like.
[0080] Although vaccination of an individual with an attenuated influenza virus of a particular strain of a particular subgroup can induce cross-protection against influenza virus of different strains and/or subgroups, cross-protection can be enhanced, if desired, by vaccinating the individual with attenuated influenza virus from at least two strains, e.g., each of which represents a different subgroup. Additionally, vaccine combinations can optionally include mixes of pandemic vaccines (e.g., those against pandemic influenza strains such as various avian strains, see, e.g., the sequences herein, or other pandemic strains) and non-pandemic strains. Vaccine mixtures (or multiple vaccinations) can comprise components from human strains and/or non-human influenza strains (e.g., avian and human, etc.). Similarly, the attenuated influenza virus vaccines of this invention can optionally be combined with vaccines that induce protective immune responses against other infectious agents.

POLYNUCLEOTIDES OF THE INVENTION

[0081] It is well known in the art that the HA and NA polynucleotide segments of influenza viruses comprise both a coding region (encoding the ORF) and noncoding regions (NCRs), both 5’ and 3’ of the HA and NA coding sequence. An example of these NCRs are shown in SEQ ID NOS:1-9 (outside of the ORFs). It is also known that primers can be made to these NCRs to facilitate amplification of the entire HA and NA segments of influenza virus. (see, e.g., Hoffmann et al. Arch Virol. 2001 Dec;146(12):2275-89). Further, it is known that the NCRs of the HA and NA of influenza may increase the efficiency of achieving reassortants. Therefore, the polynucleotide sequences of these NCRs (including fragments and variants (e.g., at least about 60%, or at least 70%, or at least 80%, or at least 90%, or at least about 91% or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 98.5%, or at least about 98.7%, or at least about 99%, or at least about 99.1%, or at least about 99.2%, or at least about 99.3%, or at least about 99.4%, or at least about 99.5%, or at least about 99.6% or at least about 99.7%, or at least about 99.8%, or at least about 99.9% identity) thereof are within the scope of this invention. When amplifying the HA and NA segments of any pandemic strain, one could make and use polynucleotide primers to bind conserved (e.g., among related strains) regions of the HA and NA NCRs for amplification (e.g., by RT-PCR). In one embodiment, HA and NA polynucleotides of the
invention include both the NCR and ORF of the HA and NA sequences (including fragments and variants (e.g., at least about 60%, or at least 70%, or at least 80%, or at least 90%, or at least about 91% or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 98.5%, or at least about 98.7%, or at least about 99%, or at least about 99.1%, or at least about 99.2%, or at least about 99.3%, or at least about 99.4%, or at least about 99.5%, or at least about 99.6% or at least about 99.7%, or at least about 99.8%, or at least about 99.9%) thereof) of pandemic virus strains. In alternative embodiments, the HA and NA polynucleotides of the invention exclude the NCR, but include the ORF (including fragments and variants (e.g., at least about 60%, or at least 70%, or at least 80%, or at least 90%, or at least about 91% or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 98.5%, or at least about 98.7%, or at least about 99%, or at least about 99.1%, or at least about 99.2%, or at least about 99.3%, or at least about 99.4%, or at least about 99.5%, or at least about 99.6% or at least about 99.7%, or at least about 99.8%, or at least about 99.9% thereof)) of the HA and NA sequences of pandemic virus strains (e.g., SEQ ID NOS: 1-9).

[0082] The HA and NA polynucleotides of the invention, e.g., SEQ ID NO:1 through SEQ ID NO:10, and fragments thereof, are optionally used in a number of different capacities alternative to, or in addition to, the vaccines described above. Other exemplary uses are described herein for illustrative purpose and not as limitations on the actual range of uses. Different methods of construction, purification, and characterization of the nucleotide sequences of the invention are also described herein. In some embodiments, nucleic acids including one or more polynucleotide sequence of the invention are favorably used as probes for the detection of corresponding or related nucleic acids in a variety of contexts, such as in nucleic hybridization experiments, e.g., to find and/or characterize homologous influenza variants (e.g., homologues to the sequences herein, etc.) infecting other species or in different influenza outbreaks, etc. The probes can be either DNA or RNA molecules, such as restriction fragments of genomic or cloned DNA, cDNAs, PCR amplification products, transcripts, and oligonucleotides, and can vary in length from oligonucleotides as short as about 10 nucleotides in length to full length sequences or cDNAs in excess of 1 kb or more. For example, in some embodiments, a probe of the invention includes a polynucleotide sequence or subsequence selected, e.g., from among
SEQ ID NO: 1 through SEQ ID NO: 10, or sequences complementary thereto. Alternatively, polynucleotide sequences that are variants of one of the above-designated sequences are used as probes. Most typically, such variants include one or a few conservative nucleotide variations. For example, pairs (or sets) of oligonucleotides can be selected, in which the two (or more) polynucleotide sequences are conservative variations of each other, wherein one polynucleotide sequence corresponds identically to a first variant or and the other(s) corresponds identically to additional variants. Such pairs of oligonucleotide probes are particularly useful, e.g., for specific hybridization experiments to detect polymorphic nucleotides or to, e.g., detect homologous influenza HA and NA variants, e.g., homologous to the current HA and NA sequences, infecting other species or present in different (e.g., either temporally and/or geographically different) influenza outbreaks. In other applications, probes are selected that are more divergent, that is probes that are at least about 91% (or about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 98.5%, about 98.7%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, or about 99.6% or more about 99.7%, about 99.8%, about 99.9% or more) identical are selected.

The probes of the invention, e.g., as exemplified by sequences derived from the sequences herein, can also be used to identify additional useful polynucleotide sequences according to procedures routine in the art. In one set of embodiments, one or more probes, as described above, are utilized to screen libraries of expression products or chromosomal segments (e.g., expression libraries or genomic libraries) to identify clones that include sequences identical to, or with significant sequence similarity to, e.g., one or more probe of the sequences herein, i.e., variants, homologues, etc. It will be understood that in addition to such physical methods as library screening, computer assisted bioinformatic approaches, e.g., BLAST and other sequence homology search algorithms, and the like, can also be used for identifying related polynucleotide sequences. Polynucleotide sequences identified in this manner are also a feature of the invention.

Oligonucleotide probes are optionally produced via a variety of methods well known to those skilled in the art. Most typically, they are produced by well known synthetic methods, such as the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981) Tetrahedron Letts 22(20):1859-1862, e.g., using an automated synthesizer, or as described in Needham-Van Devanter et al. (1984) Nucl Acids
Res. 12:6159-6168. Oligonucleotides can also be custom made and ordered from a variety of commercial sources known to persons of skill. Purification of oligonucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Regnier (1983) J Chrom 255:137-149. The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology 65:499-560. Custom oligos can also easily be ordered from a variety of commercial sources known to persons of skill.

In other circumstances, e.g., relating to attributes of cells or organisms expressing the polynucleotides and polypeptides of the invention (e.g., those harboring virus comprising the sequences of the invention), probes that are polypeptides, peptides or antibodies are favorably utilized. For example, isolated or recombinant polypeptides, polypeptide fragments and peptides derived from any of the amino acid sequences of the invention (e.g., SEQ ID NO: 11-20) and/or encoded by polynucleotide sequences of the invention, e.g., selected from SEQ ID NO: 1 through SEQ ID NO: 10, are favorably used to identify and isolate antibodies, e.g., from phage display libraries, combinatorial libraries, polyclonal sera, and the like. Polypeptide fragments of the inventions include a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, or at least 10 contiguous amino acid residues, or at least 15 contiguous amino acid residues, or at least 20 contiguous amino acid residues, or at least 25 contiguous amino acid residues, or at least 40 contiguous amino acid residues, or at least 50 contiguous amino acid residues, or at least 60 contiguous amino acid residues, or at least 70 contiguous amino acid residues, or at least 80 amino acid residues, or at least 90 amino acid residues, or at least 100 amino acid residues, or at least 125 amino acid residues, or at least 150 contiguous amino acid residues, or at least contiguous 175 amino acid residues, or at least contiguous 200 amino acid residues, or at least contiguous 250 amino acid residues, or at least contiguous 350, or at least contiguous 400, or at least contiguous 450, or at least contiguous 500, or at least contiguous 550 amino acid residues of the amino acid sequence an HA or NA polypeptide of the invention (e.g., SEQ ID Nos: 11-20). Polynucleotides encoding said polypeptide fragments and antibodies that specifically bind said polypeptides are also preferred embodiments of the invention.
Antibodies specific for any a polypeptide sequence or subsequence, e.g., of SEQ ID NO: 11 through SEQ ID NO: 20, and/or encoded by polynucleotide sequences of the invention, e.g., selected from SEQ ID NO: 1 through SEQ ID NO: 10, are likewise valuable as probes for evaluating expression products, e.g., from cells or tissues. In addition, antibodies are particularly suitable for evaluating expression of proteins comprising amino acid subsequences, e.g., of those given herein, or encoded by polynucleotides sequences of the invention, e.g., selected from those shown herein, in situ, in a tissue array, in a cell, tissue or organism, e.g., an organism infected by an unidentified influenza virus or the like. Antibodies can be directly labeled with a detectable reagent, or detected indirectly by labeling of a secondary antibody specific for the heavy chain constant region (i.e., isotype) of the specific antibody. Additional details regarding production of specific antibodies are provided below.

**Diagnostic Assays**

The nucleic acid sequences of the present invention can be used in diagnostic assays to detect influenza (and/or hemagglutinin and/or neuraminidase) in a sample, to detect hemagglutinin-like and/or neuraminidase-like sequences, and to detect strain differences in clinical isolates of influenza using either chemically synthesized or recombinant polynucleotide fragments, e.g., selected from the sequences herein. For example, fragments of the hemagglutinin and/or neuraminidase sequences comprising at least between 10 and 20 nucleotides can be used as primers to amplify nucleic acids using polymerase chain reaction (PCR) methods well known in the art (e.g., reverse transcription-PCR) and as probes in nucleic acid hybridization assays to detect target genetic material such as influenza RNA in clinical specimens.

The probes of the invention, e.g., as exemplified by unique subsequences selected from those given herein, can also be used to identify additional useful polynucleotide sequences (such as to characterize additional strains of influenza) according to procedures routine in the art. In one set of preferred embodiments, one or more probes, as described above, are utilized to screen libraries of expression products or cloned viral nucleic acids (i.e., expression libraries or genomic libraries) to identify clones that include sequences identical to, or with significant sequence identity to the sequences herein. In turn, each of these identified sequences can be used to make probes, including pairs or sets of variant probes as described above. It will be understood that in addition to such physical
methods as library screening, computer assisted bioinformatic approaches, e.g., BLAST and other sequence homology search algorithms, and the like, can also be used for identifying related polynucleotide sequences.

[0089] The probes of the invention are particularly useful for detecting the presence and for determining the identity of influenza nucleic acids in cells, tissues or other biological samples (e.g., a nasal wash or bronchial lavage). For example, the probes of the invention are favorably utilized to determine whether a biological sample, such as a subject (e.g., a human subject) or model system (such as a cultured cell sample) has been exposed to, or become infected with influenza, or particular strain(s) of influenza. Detection of hybridization of the selected probe to nucleic acids originating in (e.g., isolated from) the biological sample or model system is indicative of exposure to or infection with the virus (or a related virus) from which the probe polynucleotide is selected.

[0090] It will be appreciated that probe design is influenced by the intended application. For example, where several allele-specific probe-target interactions are to be detected in a single assay, e.g., on a single DNA chip, it is desirable to have similar melting temperatures for all of the probes. Accordingly, the lengths of the probes are adjusted so that the melting temperatures for all of the probes on the array are closely similar (it will be appreciated that different lengths for different probes may be needed to achieve a particular \( T_m \) where different probes have different GC contents). Although melting temperature is a primary consideration in probe design, other factors are optionally used to further adjust probe construction, such as selecting against primer self-complementarity and the like.

Vectors, Promoters and Expression Systems

[0091] The present invention includes recombinant constructs incorporating one or more of the nucleic acid sequences described herein. Such constructs optionally include a vector, for example, a plasmid, a cosm  id, a phage, a virus, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), etc., into which one or more of the polynucleotide sequences of the invention, e.g., comprising any of SEQ ID NO: 1 through SEQ ID NO: 10, or a subsequence thereof etc., has been inserted, in a forward or reverse orientation. For example, the inserted nucleic acid can include a viral chromosomal sequence or cDNA including all or part of at least one of the polynucleotide sequences of the invention. In one embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of
suitable vectors and promoters are known to those of skill in the art, and are commercially available.

[0092] The polynucleotides of the present invention can be included in any one of a variety of vectors suitable for generating sense or antisense RNA, and optionally, polypeptide (or peptide) expression products (e.g., a hemagglutinin and/or neuraminidase molecule of the invention, or fragments thereof). Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, adenovirus, adeno-associated virus, retroviruses and many others (e.g., pCDL). Any vector that is capable of introducing genetic material into a cell, and, if replication is desired, which is replicable in the relevant host can be used.

[0093] In an expression vector, the HA and/or NA polynucleotide sequence of interest is physically arranged in proximity and orientation to an appropriate transcription control sequence (e.g., promoter, and optionally, one or more enhancers) to direct mRNA synthesis. That is, the polynucleotide sequence of interest is operably linked to an appropriate transcription control sequence. Examples of such promoters include: LTR or SV40 promoter, E. coli lac or trp promoter, phage lambda P L promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.

[0094] A variety of promoters are suitable for use in expression vectors for regulating transcription of influenza virus genome segments. In certain embodiments, the cytomegalovirus (CMV) DNA dependent RNA Polymerase II (Pol II) promoter is utilized. If desired, e.g., for regulating conditional expression, other promoters can be substituted which induce RNA transcription under the specified conditions, or in the specified tissues or cells. Numerous viral and mammalian, e.g., human promoters are available, or can be isolated according to the specific application contemplated. For example, alternative promoters obtained from the genomes of animal and human viruses include such promoters as the adenovirus (such as Adenovirus 2), papilloma virus, hepatitis-B virus, polyoma virus, and Simian Virus 40 (SV40), and various retroviral promoters. Mammalian promoters include, among many others, the actin promoter, immunoglobulin promoters, heat-shock promoters, and the like.
[0095] Transcription is optionally increased by including an enhancer sequence. Enhancers are typically short, e.g., 10-500 bp, cis-acting DNA elements that act in concert with a promoter to increase transcription. Many enhancer sequences have been isolated from mammalian genes (hemoglobin, elastase, albumin, alpha-fetoprotein, and insulin), and eukaryotic cell viruses. The enhancer can be spliced into the vector at a position 5' or 3' to the heterologous coding sequence, but is typically inserted at a site 5' to the promoter. Typically, the promoter, and if desired, additional transcription enhancing sequences are chosen to optimize expression in the host cell type into which the heterologous DNA is to be introduced (Scharf et al. (1994) *Heat stress promoters and transcription factors Results Probl Cell Differ* 20:125-62; Kriegler et al. (1990) *Assembly of enhancers, promoters, and splice signals to control expression of transferred genes Methods in Enzymol* 185: 512-27). Optionally, the amplicon can also contain a ribosome binding site or an internal ribosome entry site (IRES) for translation initiation.

[0096] The vectors of the invention also favorably include sequences necessary for the termination of transcription and for stabilizing the mRNA, such as a polyadenylation site or a terminator sequence. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. In one embodiment, the SV40 polyadenylation signal sequences can provide a bi-directional polyadenylation site that insulates transcription of (+) strand mRNA molecules from the PolII promoter initiating replication of the (-) strand viral genome.

[0097] In addition, as described above, the expression vectors optionally include one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, in addition to genes previously listed, markers such as dihydrofolate reductase or neomycin resistance are suitable for selection in eukaryotic cell culture.

[0098] The vector containing the appropriate nucleic acid sequence as described above, as well as an appropriate promoter or control sequence, can be employed to transform a host cell permitting expression of the protein. While the vectors of the invention can be replicated in bacterial cells, most frequently it will be desirable to introduce them into mammalian cells, e.g., Vero cells, BHK cells, MDCK cell, 293 cells, COS cells, or the like, for the purpose of expression.
As described elsewhere, the HA and NA sequences herein, in various embodiments, can be comprised within plasmids involved in plasmid-rescue reassortment. See, e.g., U.S. Application Nos. 60/420,708, filed October 23, 2002; 60/574,117, filed May 24, 2004; 10/423,828, filed April 25, 2003; 60/578,962, filed June 12, 2004; and 10/870,690 filed June 16, 2004; and US20020164770, which are incorporated by reference herein. For example, preferred expression vectors of the invention include, but are not limited to, vectors comprising pol I promoter and terminator sequences or vectors using both the pol I and pol II promoters “the pol/pollII promoter system” (e.g., Zobel et al., Nucl. Acids Res. 1993, 21:3607; US20020164770; Neumann et al., Proc. Natl. Acad. Sci. USA 1999, 96:9345; Fodor et al., J. Virol. 1999, 73:9679; and US20030035814). The reassortants produced can include the HA and NA genes arranged with the 6 other influenza genes from the A/Ann Arbor/6/60 donor strain (and/or derivatives and modifications thereof), the PR8 donor strain backbone, the A/Leningrad/17 donor strain backbone, etc. Other backbone strains are described, for example, in 20040137013 and 20030147916, which are incorporated by reference herein.

Additional Expression Elements

Most commonly, the genome segment encoding the influenza virus HA and/or NA protein includes any additional sequences necessary for its expression, including translation into a functional viral protein. In other situations, a minigene, or other artificial construct encoding the viral proteins, e.g., an HA and/or NA protein, can be employed. Again, in such case, it is often desirable to include specific initiation signals that aid in the efficient translation of the heterologous coding sequence. These signals can include, e.g., the ATG initiation codon and adjacent sequences. To insure translation of the entire insert, the initiation codon is inserted in the correct reading frame relative to the viral protein.

Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use.

If desired, polynucleotide sequences encoding additional expressed elements, such as signal sequences, secretion or localization sequences, and the like, can be incorporated into the vector, usually, in-frame with the polynucleotide sequence of interest, e.g., to target polypeptide expression to a desired cellular compartment, membrane, or organelle, or to direct polypeptide secretion to the periplasmic space or into the cell culture
media. Such sequences are known to those of skill, and include secretion leader peptides, organelle targeting sequences (e.g., nuclear localization sequences, ER retention signals, mitochondrial transit sequences), membrane localization/anchor sequences (e.g., stop transfer sequences, GPI anchor sequences), and the like.

Where translation of a polypeptide encoded by a nucleic acid sequence of the invention is desired, additional translation specific initiation signals can improve the efficiency of translation. These signals can include, e.g., an ATG initiation codon and adjacent sequences, an IRES region, etc. In some cases, for example, full-length cDNA molecules or chromosomal segments including a coding sequence incorporating, e.g., a polynucleotide sequence of the invention (e.g., as in the sequences herein), a translation initiation codon and associated sequence elements are inserted into the appropriate expression vector simultaneously with the polynucleotide sequence of interest. In such cases, additional translational control signals frequently are not required. However, in cases where only a polypeptide coding sequence, or a portion thereof, is inserted, exogenous translational control signals, including, e.g., an ATG initiation codon is often provided for expression of the relevant sequence. The initiation codon is put in the correct reading frame to ensure transcription of the polynucleotide sequence of interest. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use (see, e.g., Scharf D. et al. (1994) Results Probl Cell Differ 20:125-62; Bittner et al. (1987) Methods in Enzymol 153:516-544).

Production of recombinant virus

(1997) Virology 237:249-260); canine distemper virus (Gassen et al. 2000) J. Virol. 74:10737-44); and Sendai virus (Park et al. 1991) Proc. Natl. Acad. Sci. USA 88: 5537-5541; Kato et al. 1996) Genes to Cells 1:569-579). Those of skill in the art will be familiar with these and similar techniques to produce influenza virus comprising the HA and NA sequences of the invention. Recombinant influenza viruses produced according to such methods are also a feature of the invention, as are recombinant influenza virus comprising one or more nucleic acids and/or polypeptides of the invention.

**Cell Culture and Expression Hosts**

The present invention also relates to host cells that are introduced (transduced, transformed or transfected) with vectors of the invention, and the production of polypeptides of the invention by recombinant techniques. Host cells are genetically engineered (i.e., transduced, transformed or transfected) with a vector, such as an expression vector, of this invention. As described above, the vector can be in the form of a plasmid, a viral particle, a phage, etc. Examples of appropriate expression hosts include: bacterial cells, such as *E. coli*, *Streptomyces*, and *Salmonella typhimurium*; fungal cells, such as *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Neurospora crassa*; or insect cells such as *Drosophila* and *Spodoptera frugiperda*.

Most commonly, mammalian cells are used to culture the HA and NA molecules of the invention. Suitable host cells for the replication of influenza virus include, e.g., Vero cells, BHK cells, MDCK cells, 293 cells and COS cells, including 293T cells, COS7 cells or the like. Commonly, co-cultures including two of the above cell lines, e.g., MDCK cells and either 293T or COS cells are employed at a ratio, e.g., of 1:1, to improve replication efficiency. Typically, cells are cultured in a standard commercial culture medium, such as Dulbecco’s modified Eagle’s medium supplemented with serum (e.g., 10% fetal bovine serum), or in serum free medium, under controlled humidity and CO₂ concentration suitable for maintaining neutral buffered pH (e.g., at pH between 7.0 and 7.2). Optionally, the medium contains antibiotics to prevent bacterial growth, e.g., penicillin, streptomycin, etc., and/or additional nutrients, such as L-glutamine, sodium pyruvate, non-essential amino acids, additional supplements to promote favorable growth characteristics, e.g., trypsin, β-mercaptoethanol, and the like.

The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the
inserted polynucleotide sequences. The culture conditions, such as temperature, pH and the like, are typically those previously used with the particular host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, e.g., Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, 3rd edition, Wiley- Liss, New York and the references cited therein. Other helpful references include, e.g., Paul (1975) Cell and Tissue Culture, 5th ed., Livingston, Edinburgh; Adams (1980) Laboratory Techniques in Biochemistry and Molecular Biology-Cell Culture for Biochemists, Work and Burdon (eds.) Elsevier, Amsterdam. Additional details regarding tissue culture procedures of particular interest in the production of influenza virus in vitro include, e.g., Merten et al. (1996) Production of influenza virus in cell cultures for vaccine preparation. in Cohen and Shafferman (eds.) Novel Strategies in Design and Production of Vaccines, which is incorporated herein in its entirety for all purposes. Additionally, variations in such procedures adapted to the present invention are readily determined through routine experimentation and will be familiar to those skilled in the art.

Cells for production of influenza virus (e.g., having the HA and/or NA sequences of the invention) can be cultured in serum-containing or serum free medium. In some case, e.g., for the preparation of purified viruses, it is typically desirable to grow the host cells in serum free conditions. Cells can be cultured in small scale, e.g., less than 25 ml medium, culture tubes or flasks or in large flasks with agitation, in rotator bottles, or on microcarrier beads (e.g., DEAE-Dextran microcarrier beads, such as Dormacell, Pfeifer & Langen; Superbead, Flow Laboratories; styrene copolymer-tri-methylamine beads, such as Hillex, SoloHill, Ann Arbor) in flasks, bottles or reactor cultures. Microcarrier beads are small spheres (in the range of 100-200 microns in diameter) that provide a large surface area for adherent cell growth per volume of cell culture. For example a single liter of medium can include more than 20 million microcarrier beads providing greater than 8000 square centimeters of growth surface. For commercial production of viruses, e.g., for vaccine production, it is often desirable to culture the cells in a bioreactor or fermenter. Bioreactors are available in volumes from under 1 liter to in excess of 100 liters, e.g., Cyto3 Bioreactor (Osmonics, Minnetonka, MN); NBS bioreactors (New Brunswick Scientific, Edison, NJ); laboratory and commercial scale bioreactors from B. Braun Biotech International (B. Braun Biotech, Melsungen, Germany).
Regardless of the culture volume, in many desired aspects of the current invention, it is important that the cultures be maintained at an appropriate temperature, to insure efficient recovery of recombinant and/or reassortant influenza virus using temperature dependent multi plasmid systems (see, e.g., Multi-Plasmid System for the Production of Influenza Virus, U.S. Application No. 60/420,708, filed October 23, 2002, U.S. Application No. 10/423,828, filed April 25, 2003, and U.S. Application No. 60/574,117, filed May 24, 2004), heating of virus solutions for filtration, etc. Typically, a regulator, e.g., a thermostat, or other device for sensing and maintaining the temperature of the cell culture system and/or other solution, is employed to insure that the temperature is at the correct level during the appropriate period (e.g., virus replication, etc.).

In some embodiments herein (e.g., wherein reassorted viruses are to be produced from segments on vectors) vectors comprising influenza genome segments are introduced (e.g., transfected) into host cells according to methods well known in the art for introducing heterologous nucleic acids into eukaryotic cells, including, e.g., calcium phosphate co-precipitation, electroporation, microinjection, lipofection, and transfection employing polyamine transfection reagents. For example, vectors, e.g., plasmids, can be transfected into host cells, such as COS cells, 293T cells or combinations of COS or 293T cells and MDCK cells, using the polyamine transfection reagent TransIT-LT1 (Mirus) according to the manufacturer’s instructions in order to produce reassorted viruses, etc.

Thus, in one example, approximately 1 μg of each vector is introduced into a population of host cells with approximately 2 μl of TransIT-LT1 diluted in 160 μl medium, preferably serum-free medium, in a total volume of 200 μl. The DNA:transfection reagent mixtures are incubated at room temperature for 45 minutes followed by addition of 800 μl of medium. The transfection mixture is added to the host cells, and the cells are cultured as described via other methods well known to those skilled in the art. Accordingly, for the production of recombinant or reassortant viruses in cell culture, vectors incorporating each of the 8 genome segments, (PB2, PB1, PA, NP, M, NS, HA and NA, e.g., of the invention) are mixed with approximately 20 μl TransIT-LT1 and transfected into host cells. Optionally, serum-containing medium is replaced prior to transfection with serum-free medium, e.g., Opti-MEM I, and incubated for 4-6 hours.

Alternatively, electroporation can be employed to introduce such vectors incorporating influenza genome segments into host cells. For example, plasmid vectors
incorporating an influenza A or influenza B virus are favorably introduced into Vero cells using electroporation according to the following procedure. In brief, approximately $5 \times 10^6$ Vero cells, e.g., grown in Modified Eagle's Medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS) are resuspended in 0.4 ml OptiMEM and placed in an electroporation cuvette. Twenty micrograms of DNA in a volume of up to 25 μl is added to the cells in the cuvette, which is then mixed gently by tapping. Electroporation is performed according to the manufacturer's instructions (e.g., BioRad Gene Pulser II with Capacitance Extender Plus connected) at 300 volts, 950 microFarads with a time constant of between 28-33 msec. The cells are remixed by gently tapping and approximately 1-2 minutes following electroporation 0.7 ml MEM with 10% FBS is added directly to the cuvette. The cells are then transferred to two wells of a standard 6 well tissue culture dish containing 2 ml MEM, 10% FBS. The cuvette is washed to recover any remaining cells and the wash suspension is divided between the two wells. Final volume is approximately 3.5 ml. The cells are then incubated under conditions permissive for viral growth, e.g., at approximately 33 °C for cold adapted strains.

In mammalian host cells, a number of expression systems, such as viral-based systems, can be utilized. In cases where an adenovirus is used as an expression vector, a coding sequence is optionally ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing the polypeptides of interest in infected host cells (Logan and Shenk (1984) Proc Natl Acad Sci 81:3655-3659). In addition, transcription enhancers, such as the rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

A host cell strain is optionally chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing, which cleaves a precursor form into a mature form, of the protein is sometimes important for correct insertion, folding and/or function. Additionally proper location within a host cell (e.g., on the cell surface) is also important. Different host cells such as COS, CHO, BHK, MDCK, 293, 293T, COS7, etc. have specific cellular machinery and
characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modification and processing of the current introduced, foreign protein.

[0113] For long-term, high-yield production of recombinant proteins encoded by, or having subsequences encoded by, the polynucleotides of the invention, stable expression systems are optionally used. For example, cell lines, stably expressing a polypeptide of the invention, are transfected using expression vectors that contain viral origins of replication or endogenous expression elements and a selectable marker gene. For example, following the introduction of the vector, cells are allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Thus, resistant clumps of stably transformed cells, e.g., derived from single cell type, can be proliferated using tissue culture techniques appropriate to the cell type.

[0114] Host cells transformed with a nucleotide sequence encoding a polypeptide of the invention are optionally cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The cells expressing said protein can be sorted, isolated and/or purified. The protein or fragment thereof produced by a recombinant cell can be secreted, membrane-bound, or retained intracellularly, depending on the sequence (e.g., depending upon fusion proteins encoding a membrane retention signal or the like) and/or the vector used.


[0116] In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the expressed product. For example, when large quantities of a polypeptide or fragments thereof are needed for the production of antibodies,
vectors that direct high-level expression of fusion proteins that are readily purified are favorably employed. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the coding sequence of interest, e.g., sequences comprising those found herein, etc., can be ligated into the vector in-frame with sequences for the amino-terminal translation initiating methionine and the subsequent 7 residues of beta-galactosidase producing a catalytically active beta galactosidase fusion protein; pIN vectors (Van Hecke & Schuster (1989) *J Biol Chem* 264:5503-5509); pET vectors (Novagen, Madison WI); and the like. Similarly, in the yeast *Saccharomyces cerevisiae* a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH can be used for production of the desired expression products. For reviews, see Ausubel, *infra*, and Grant et al., (1987); Methods in Enzymology 153:516-544.

**Nucleic Acid Hybridization**

Comparative hybridization can be used to identify nucleic acids (e.g., SEQ ID NO: 1-10) of the invention, including conservative variations of nucleic acids of the invention. This comparative hybridization method is a preferred method of distinguishing nucleic acids of the invention. In addition, target nucleic acids which hybridize to the nucleic acids represented by, e.g., those shown herein under high, ultra-high and ultra-ultra-high stringency conditions are features of the invention. Examples of such nucleic acids include those with one or a few silent or conservative nucleic acid substitutions as compared to a given nucleic acid sequence.

A test target nucleic acid is said to specifically hybridize to a probe nucleic acid when it hybridizes at least one-half as well to the probe as to the perfectly matched complementary target, i.e., with a signal to noise ratio at least one-half as high as hybridization of the probe and target under conditions in which a perfectly matched probe binds to a perfectly matched complementary target with a signal to noise ratio that is at least about 5x-10x as high as that observed for hybridization to any of the unmatched target nucleic acids.

Nucleic acids “hybridize” when they associate, typically in solution. Nucleic acids hybridize due to a variety of well-characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. Numerous protocols for nucleic acid hybridization are well known in the art. An extensive guide to the

[0120] An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of stringent wash conditions comprises a 0.2x SSC wash at 65°C for 15 minutes (see, Sambrook, infra for a description of SSC buffer and other nucleic acid hybridization parameters). Often the high stringency wash is preceded by a low stringency wash to remove background probe signal. An example low stringency wash is 2x SSC at 40°C for 15 minutes. In general, a signal to noise ratio of 5x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

[0121] After hybridization, unhybridized nucleic acids can be removed by a series of washes, the stringency of which can be adjusted depending upon the desired results. Low stringency washing conditions (e.g., using higher salt and lower temperature) increase sensitivity, but can produce nonspecific hybridization signals and high background signals. Higher stringency conditions (e.g., using lower salt and higher temperature that is closer to the T_m) lower the background signal, typically with primarily the specific signal remaining. See, also, Rapley, R. and Walker, J.M. eds., Molecular Biotechniques Handbook (Humana Press, Inc. 1998).

[0122] “Stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993), supra, and in Hames and
Higgins, 1 and 2. Stringent hybridization and wash conditions can easily be determined empirically for any test nucleic acid. For example, in determining highly stringent hybridization and wash conditions, the hybridization and wash conditions are gradually increased (e.g., by increasing temperature, decreasing salt concentration, increasing detergent concentration and/or increasing the concentration of organic solvents such as formalin in the hybridization or wash), until a selected set of criteria is met. For example, the hybridization and wash conditions are gradually increased until a probe binds to a perfectly matched complementary target with a signal to noise ratio that is at least 5x as high as that observed for hybridization of the probe to an unmatched target.

In general, a signal to noise ratio of at least 2x (or higher, e.g., at least 5x, 10x, 20x, 50x, 100x, or more) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Detection of at least stringent hybridization between two sequences in the context of the present invention indicates relatively strong structural similarity to, e.g., the nucleic acids of the present invention provided in the sequence listings herein.

"Very stringent" conditions are selected to be equal to the thermal melting point (T_m) for a particular probe. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the test sequence hybridizes to a perfectly matched probe. For the purposes of the present invention, generally, "highly stringent" hybridization and wash conditions are selected to be about 5°C lower than the T_m for the specific sequence at a defined ionic strength and pH (as noted below, highly stringent conditions can also be referred to in comparative terms). Target sequences that are closely related or identical to the nucleotide sequence of interest (e.g., "probe") can be identified under stringent or highly stringent conditions. Lower stringency conditions are appropriate for sequences that are less complementary.

"Ultra high-stringency" hybridization and wash conditions are those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of a probe to a perfectly matched complementary target nucleic acid is at least 10x as high as that observed for hybridization to any unmatched target nucleic acids.

A target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least one-half that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-high stringency conditions.
In determining stringent or highly stringent hybridization (or even more stringent hybridization) and wash conditions, the hybridization and wash conditions are gradually increased (e.g., by increasing temperature, decreasing salt concentration, increasing detergent concentration and/or increasing the concentration of organic solvents, such as formamide, in the hybridization or wash), until a selected set of criteria are met. For example, the hybridization and wash conditions are gradually increased until a probe comprising one or more polynucleotide sequences of the invention, e.g., sequences or unique subsequences selected from those given herein (e.g., SEQ ID NO: 1-10) and/or complementary polynucleotide sequences, binds to a perfectly matched complementary target (again, a nucleic acid comprising one or more nucleic acid sequences or subsequences selected from those given herein and/or complementary polynucleotide sequences thereof), with a signal to noise ratio that is at least 2x (and optionally 5x, 10x, or 100x or more) as high as that observed for hybridization of the probe to an unmatched target (e.g., a polynucleotide sequence comprising one or more sequences or subsequences selected from known influenza sequences present in public databases such as GenBank at the time of filing, and/or complementary polynucleotide sequences thereof), as desired.

Using the polynucleotides of the invention, or subsequences thereof, novel target nucleic acids can be obtained; such target nucleic acids are also a feature of the invention. For example, such target nucleic acids include sequences that hybridize under stringent conditions to a unique oligonucleotide probe corresponding to any of the polynucleotides of the invention, e.g., SEQ ID NO: 1-10).

Similarly, even higher levels of stringency can be determined by gradually increasing the hybridization and/or wash conditions of the relevant hybridization assay. For example, those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least 10X, 20X, 50X, 100X, or 500X or more as high as that observed for hybridization to any unmatched target nucleic acids. The particular signal will depend on the label used in the relevant assay, e.g., a fluorescent label, a colorimetric label, a radioactive label, or the like. A target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least one-half that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-ultra-high stringency conditions and are also features of the invention.
[0129] Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

5

Cloning, Mutagenesis and Expression of Biomolecules of Interest

[0130] General texts which describe molecular biological techniques, which are applicable to the present invention, such as cloning, mutation, cell culture and the like, include Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook et al., Molecular Cloning - A Laboratory Manual (3rd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2000 ("Sambrook") and Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2002) ("Ausubel"). These texts describe mutagenesis, the use of vectors, promoters and many other relevant topics related to, e.g., the generation of HA and/or NA molecules, etc.

10

[0131] Various types of mutagenesis are optionally used in the present invention, e.g., to produce and/or isolate, e.g., novel or newly isolated HA and/or NA molecules and/or to further modify/mutate the polypeptides (e.g., HA and NA molecules as in SEQ ID NO: 11-20) of the invention. They include but are not limited to site-directed, random point mutagenesis, homologous recombination (DNA shuffling), mutagenesis using uracil containing templates, oligonucleotide-directed mutagenesis, phosphorothioate-modified DNA mutagenesis, mutagenesis using gapped duplex DNA or the like. Additional suitable methods include point mismatch repair, mutagenesis using repair-deficient host strains, restriction-selection and restriction-purification, deletion mutagenesis, mutagenesis by total gene synthesis, double-strand break repair, and the like. Mutagenesis, e.g., involving chimeric constructs, is also included in the present invention. In one embodiment, mutagenesis can be guided by known information of the naturally occurring molecule or altered or mutated naturally occurring molecule, e.g., sequence, sequence comparisons, physical properties, crystal structure or the like.

20

[0132] The above texts and examples found herein describe these procedures as well as the following publications (and references cited within): Sieber, et al., Nature Biotechnology, 19:456-460 (2001); Ling et al., Approaches to DNA mutagenesis: an

[0133] Oligonucleotides, e.g., for use in mutagenesis of the present invention, e.g., mutating libraries of the HA and/or NA molecules of the invention, or altering such, are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage and Caruthers, Tetrahedron Letts 22(20):1859-1862, (1981) e.g., using an automated synthesizer, as described in Needham-VanDevanter et al., Nucleic Acids Res, 12:6159-6168 (1984).

[0134] In addition, essentially any nucleic acid can be custom or standard ordered from any of a variety of commercial sources, such as The Midland Certified Reagent Company (mcrc@oligos.com), The Great American Gene Company (www.genco.com), ExpressGen Inc. (www.expressgen.com), Operon Technologies Inc. (Alameda, CA) and many others. Similarly, peptides and antibodies can be custom ordered from any of a
variety of sources, such as PeptidoGenic (available at pkim@ccnet.com), HTI Bio-products, Inc. (www.htbio.com), BMA Biomedicals Ltd. (U.K.), Bio.Synthesis, Inc., and many others.

The present invention also relates to host cells and organisms comprising a HA and/or NA molecule or other polypeptide and/or nucleic acid of the invention, e.g., SEQ ID NO:1-20. Host cells are genetically engineered (e.g., transformed, transduced or transfected) with the vectors of this invention, which can be, for example, a cloning vector or an expression vector. The vector can be, for example, in the form of a plasmid, a bacterium, a virus, a naked polynucleotide, or a conjugated polynucleotide. The vectors are introduced into cells and/or microorganisms by standard methods including electroporation (see, From et al., *Proc Natl Acad Sci USA* 82, 5824 (1985), infection by viral vectors, high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein et al., *Nature* 327, 70-73 (1987)). Berger, Sambrook, and Ausubel provide a variety of appropriate transformation methods.

Several well-known methods of introducing target nucleic acids into bacterial cells are available, any of which can be used in the present invention. These include: fusion of the recipient cells with bacterial protoplasts containing the DNA, electroporation, projectile bombardment, and infection with viral vectors, etc. Bacterial cells can be used to amplify the number of plasmids containing DNA constructs of this invention. The bacteria are grown to log phase and the plasmids within the bacteria can be isolated by a variety of methods known in the art (see, for instance, Sambrook). In addition, a plethora of kits are commercially available for the purification of plasmids from bacteria, (see, e.g., EasyPrep™, FlexiPrep™, both from Pharmacia Biotech; StrataClean™, from Stratagene; and, QIAprep™ from Qiagen). The isolated and purified plasmids are then further manipulated to produce other plasmids, used to transfect cells or incorporated into related vectors to infect organisms. Typical vectors contain transcription and translation terminators, transcription and translation initiation sequences, and promoters useful for regulation of the expression of the particular target nucleic acid. The vectors optionally comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in eukaryotes, or prokaryotes, or both, (e.g., shuttle vectors) and selection markers for both prokaryotic and eukaryotic

**POLYPEPTIDE PRODUCTION AND RECOVERY**

[0137] Following transduction of a suitable host cell line or strain and growth of the host cells to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. In some embodiments, a secreted polypeptide product, e.g., a HA and/or NA polypeptide as in a secreted fusion protein form, etc., is then recovered from the culture medium. In other embodiments, a virus particle containing a HA and/or a NA polypeptide of the invention is produced from the cell. Alternatively, cells can be harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Eukaryotic or microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art. Additionally, cells expressing a HA and/or a NA polypeptide product of the invention can be utilized without separating the polypeptide from the cell. In such situations, the polypeptide of the invention is optionally expressed on the cell surface and is examined thus (e.g., by having HA and/or NA molecules (or fragments thereof, e.g., comprising fusion proteins or the like) on the cell surface bind antibodies, etc. Such cells are also features of the invention.

[0138] Expressed polypeptides can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate

When the expressed polypeptides of the invention are produced in viruses, the viruses are typically recovered from the culture medium, in which infected (transfected) cells have been grown. Typically, crude medium is clarified prior to concentration of influenza viruses. Common methods include ultrafiltration, adsorption on barium sulfate and elution, and centrifugation. For example, crude medium from infected cultures can first be clarified by centrifugation at, e.g., 1000-2000 x g for a time sufficient to remove cell debris and other large particulate matter, e.g., between 10 and 30 minutes. Optionally, the clarified medium supernatant is then centrifuged to pellet the influenza viruses, e.g., at 15,000 x g, for approximately 3-5 hours. Following resuspension of the virus pellet in an appropriate buffer, such as STE (0.01 M Tris-HCl; 0.15 M NaCl; 0.0001 M EDTA) or phosphate buffered saline (PBS) at pH 7.4, the virus is concentrated by density gradient centrifugation on sucrose (60%-12%) or potassium tartrate (50%-10%). Either continuous or step gradients, e.g., a sucrose gradient between 12% and 60% in four 12% steps, are suitable. The gradients are centrifuged at a speed, and for a time, sufficient for the viruses to concentrate into a visible band for recovery. Alternatively, and for most large-scale commercial applications, virus is elutriated from density gradients using a zonal-centrifuge
rotor operating in continuous mode. Additional details sufficient to guide one of skill through the preparation of influenza viruses from tissue culture are provided, e.g., in Furminger. Vaccine Production, in Nicholson et al. (eds.) Textbook of Influenza pp. 324-332; Merten et al. (1996) Production of influenza virus in cell cultures for vaccine preparation, in Cohen & Shafferman (eds.) Novel Strategies in Design and Production of Vaccines pp. 141-151, and United States Patent No. 5,690,937. If desired, the recovered viruses can be stored at -80° C in the presence of sucrose-phosphate-glutamate (SPG) as a stabilizer.

Alternatively, cell-free transcription/translation systems can be employed to produce polypeptides comprising an amino acid sequence or subsequence of, e.g., the sequences given herein such as SEQ ID NO: 11-20, or encoded by the polynucleotide sequences of the invention, e.g., SEQ ID NO: 1-10. A number of suitable in vitro transcription and translation systems are commercially available. A general guide to in vitro transcription and translation protocols is found in Tymms (1995) In vitro Transcription and Translation Protocols: Methods in Molecular Biology Volume 37, Garland Publishing, NY.

In addition, the polypeptides, or subsequences thereof, e.g., subsequences comprising antigenic peptides, can be produced manually or by using an automated system, by direct peptide synthesis using solid-phase techniques (see, Stewart et al. (1969) Solid-Phase Peptide Synthesis. WH Freeman Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154). Exemplary automated systems include the Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City, CA). If desired, subsequences can be chemically synthesized separately, and combined using chemical methods to provide full-length polypeptides.

Modified Amino Acids

Expressed polypeptides of the invention can contain one or more modified amino acids. The presence of modified amino acids can be advantageous in, for example, (a) increasing polypeptide serum half-life, (b) reducing/increasing polypeptide antigenicity, (c) increasing polypeptide storage stability, etc. Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production (e.g., N-linked glycosylation at N-X-S/T motifs during expression in mammalian cells) or modified by synthetic means (e.g., via PEGylation).
Non-limiting examples of a modified amino acid include a glycosylated amino acid, a sulfated amino acid, a prenylated (e.g., farnesylated, geranylgeranylated) amino acid, an acetylated amino acid, an acylated amino acid, a PEG-ylated amino acid, a biotinylated amino acid, a carboxylated amino acid, a phosphorylated amino acid, and the like, as well as amino acids modified by conjugation to, e.g., lipid moieties or other organic derivatizing agents. References adequate to guide one of skill in the modification of amino acids are replete throughout the literature. Example protocols are found in Walker (1998) Protein Protocols on CD-ROM Human Press, Towata, NJ.

Fusion Proteins

The present invention also provides fusion proteins comprising fusions of the sequences of the invention (e.g., encoding HA and/or NA polypeptides as exampled by SEQ ID NO: 11-20) or fragments thereof with, e.g., immunoglobulins (or portions thereof), sequences encoding, e.g., GFP (green fluorescent protein), or other similar markers, etc. Nucleotide sequences encoding such fusion proteins are another aspect of the invention. Fusion proteins of the invention are optionally used for, e.g., similar applications (including, e.g., therapeutic, prophylactic, diagnostic, experimental, etc. applications as described herein) as the non-fusion proteins of the invention. In addition to fusion with immunoglobulin sequences and marker sequences, the proteins of the invention are also optionally fused with, e.g., sequences which allow sorting of the fusion proteins and/or targeting of the fusion proteins to specific cell types, regions, etc.

Antibodies

The polypeptides of the invention can be used to produce antibodies specific for the polypeptides given herein and/or polypeptides encoded by the polynucleotides of the invention, e.g., those shown herein, and conservative variants thereof. Antibodies specific for the above mentioned polypeptides are useful, e.g., for diagnostic and therapeutic purposes, e.g., related to the activity, distribution, and expression of target polypeptides.

Antibodies specific for the polypeptides of the invention can be generated by methods well known in the art. Such antibodies can include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library.
Polypeptides do not require biological activity for antibody production (e.g., full length functional hemagglutinin or neuraminidase is not required). However, the polypeptide or oligopeptide must be antigenic. Peptides used to induce specific antibodies typically have an amino acid sequence of at least about 4 amino acids, and often at least 5 or 10 amino acids. Short stretches of a polypeptide can be fused with another protein, such as keyhole limpet hemocyanin, and antibody produced against the chimeric molecule.


Additional details regarding specific procedures can be found, e.g., in Ostberg et al. (1983), Hybridoma 2: 361-367, Ostberg, U.S. Pat. No. 4,634,664, and Engelman et al., U.S. Pat. No. 4,634,666.
Defining Polypeptides by Immunoreactivity

[0150] Because the polypeptides of the invention provide a variety of new polypeptide sequences (e.g., comprising HA and NA molecules), the polypeptides also provide new structural features which can be recognized, e.g., in immunological assays. The generation of antisera which specifically bind the polypeptides of the invention, as well as the polypeptides which are bound by such antisera, are features of the invention.

[0151] For example, the invention includes polypeptides (e.g., HA and NA molecules) that specifically bind to or that are specifically immunoreactive with an antibody or antisera generated against an immunogen comprising an amino acid sequence selected from one or more of the sequences given herein (e.g., SEQ ID NO: 11-20), etc. To eliminate cross-reactivity with other homologues, the antibody or antisera is subtracted with the HA and/or NA molecules found in public databases at the time of filing, e.g., the “control” polypeptide(s). Where the other control sequences correspond to a nucleic acid, a polypeptide encoded by the nucleic acid is generated and used for antibody/antisera subtraction purposes.

[0152] In one typical format, the immunoassay uses a polyclonal antiserum which was raised against one or more polypeptide comprising one or more of the sequences corresponding to the sequences herein (e.g., SEQ ID NO: 11-20), etc. or a substantial subsequence thereof (i.e., at least about 30% of the full length sequence provided). The set of potential polypeptide immunogens derived from the present sequences are collectively referred to below as “the immunogenic polypeptides.” The resulting antisera is optionally selected to have low cross-reactivity against the control hemagglutinin and/or neuraminidase homologues and any such cross-reactivity is removed, e.g., by immunoabsorption, with one or more of the control hemagglutinin and neuraminidase homologues, prior to use of the polyclonal antiserum in the immunoassay.

[0153] In order to produce antisera for use in an immunoassay, one or more of the immunogenic polypeptides is produced and purified as described herein. For example, recombinant protein can be produced in a recombinant cell. An inbred strain of mice (used in this assay because results are more reproducible due to the virtual genetic identity of the mice) is immunized with the immunogenic protein(s) in combination with a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor
Publications, New York, for a standard description of antibody generation, immunoassay formats and conditions that can be used to determine specific immunoreactivity). Additional references and discussion of antibodies is also found herein and can be applied here to defining polypeptides by immunoreactivity. Alternatively, one or more synthetic or recombinant polypeptide derived from the sequences disclosed herein is conjugated to a carrier protein and used as an immunogen.

[0154] Polyclonal sera are collected and titered against the immunogenic polypeptide in an immunoassay, for example, a solid phase immunoassay with one or more of the immunogenic proteins immobilized on a solid support. Polyclonal antisera with a titer of 10^6 or greater are selected, pooled and subtracted with the control hemagglutinin and/or neuraminidase polypeptide(s) to produce subtracted pooled titered polyclonal antisera.

[0155] The subtracted pooled titered polyclonal antisera are tested for cross reactivity against the control homologue(s) in a comparative immunoassay. In this comparative assay, discriminatory binding conditions are determined for the subtracted titered polyclonal antisera which result in at least about a 5-10 fold higher signal to noise ratio for binding of the titered polyclonal antisera to the immunogenic polypeptides as compared to binding to the control homologues. That is, the stringency of the binding reaction is adjusted by the addition of non-specific competitors such as albumin or non-fat dry milk, and/or by adjusting salt conditions, temperature, and/or the like. These binding conditions are used in subsequent assays for determining whether a test polypeptide (a polypeptide being compared to the immunogenic polypeptides and/or the control polypeptides) is specifically bound by the pooled subtracted polyclonal antisera. In particular, test polypeptides which show at least a 2-5x higher signal to noise ratio than the control receptor homologues under discriminatory binding conditions, and at least about a ½ signal to noise ratio as compared to the immunogenic polypeptide(s), shares substantial structural similarity with the immunogenic polypeptide as compared to the known receptor, etc., and is, therefore a polypeptide of the invention.

[0156] In another example, immunoassays in the competitive binding format are used for detection of a test polypeptide. For example, as noted, cross-reacting antibodies are removed from the pooled antisera mixture by immunoabsorption with the control polypeptides. The immunogenic polypeptide(s) are then immobilized to a solid support.
which is exposed to the subtracted pooled antisera. Test proteins are added to the assay to compete for binding to the pooled subtracted antisera. The ability of the test protein(s) to compete for binding to the pooled subtracted antisera as compared to the immobilized protein(s) is compared to the ability of the immunogenic polypeptide(s) added to the assay to compete for binding (the immunogenic polypeptides compete effectively with the immobilized immunogenic polypeptides for binding to the pooled antisera). The percent cross-reactivity for the test proteins is calculated, using standard calculations.

[0157] In a parallel assay, the ability of the control protein(s) to compete for binding to the pooled subtracted antisera is optionally determined as compared to the ability of the immunogenic polypeptide(s) to compete for binding to the antisera. Again, the percent cross-reactivity for the control polypeptide(s) is calculated, using standard calculations. Where the percent cross-reactivity is at least 5-10x as high for the test polypeptides as compared to the control polypeptide(s) and or where the binding of the test polypeptides is approximately in the range of the binding of the immunogenic polypeptides, the test polypeptides are said to specifically bind the pooled subtracted antisera.

[0158] In general, the immunoabsorbed and pooled antisera can be used in a competitive binding immunoassay as described herein to compare any test polypeptide to the immunogenic and/or control polypeptide(s). In order to make this comparison, the immunogenic, test and control polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the subtracted antisera to, e.g., an immobilized control, test or immunogenic protein is determined using standard techniques. If the amount of the test polypeptide required for binding in the competitive assay is less than twice the amount of the immunogenic polypeptide that is required, then the test polypeptide is said to specifically bind to an antibody generated to the immunogenic protein, provided the amount is at least about 5-10x as high as for the control polypeptide.

[0159] As an additional determination of specificity, the pooled antisera is optionally fully immunosorbed with the immunogenic polypeptide(s) (rather than the control polypeptide(s)) until little or no binding of the resulting immunogenic polypeptide subtracted pooled antisera to the immunogenic polypeptide(s) used in the immunosorption is detectable. This fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If little or no reactivity is observed (i.e., no more than 2x the signal to noise...
ratio observed for binding of the fully immunosorbed antisera to the immunogenic polypeptide), then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

NUCLEIC ACID AND POLYPEPTIDE SEQUENCE VARIANTS

[0160] As described herein, the invention provides for nucleic acid polynucleotide sequences and polypeptide amino acid sequences, e.g., hemagglutinin and neuraminidase sequences, and, e.g., compositions and methods comprising said sequences. Examples of said sequences are disclosed herein (e.g., SEQ ID NO: 1-20). However, one of skill in the art will appreciate that the invention is not necessarily limited to those sequences disclosed herein and that the present invention also provides many related and unrelated sequences with the functions described herein, e.g., encoding a HA and/or a NA molecule.

[0161] One of skill will also appreciate that many variants of the disclosed sequences are included in the invention. For example, conservative variations of the disclosed sequences that yield a functionally identical sequence are included in the invention. Variants of the nucleic acid polynucleotide sequences, wherein the variants hybridize to at least one disclosed sequence, are considered to be included in the invention. Unique subsequences of the sequences disclosed herein, as determined by, e.g., standard sequence comparison techniques, are also included in the invention.

Silent Variations

[0162] Due to the degeneracy of the genetic code, any of a variety of nucleic acid sequences encoding polypeptides and/or viruses of the invention are optionally produced, some which can bear lower levels of sequence identity to the HA and NA nucleic acid and polypeptide sequences herein. The following provides a typical codon table specifying the genetic code, found in many biology and biochemistry texts.
The codon table shows that many amino acids are encoded by more than one codon. For example, the codons AGA, AGG, CGA, CGC, CGG, and CGU all encode the amino acid arginine. Thus, at every position in the nucleic acids of the invention where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described above without altering the encoded polypeptide. It is understood that U in an RNA sequence corresponds to T in a DNA sequence.

Such “silent variations” are one species of “conservatively modified variations,” discussed below. One of skill will recognize that each codon in a nucleic acid (except ATG, which is ordinarily the only codon for methionine, and TTG, which is ordinarily the only codon for tryptophan) can be modified by standard techniques to encode a functionally identical polypeptide. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in any described sequence. The invention, therefore, explicitly provides each and every possible variation of a nucleic acid sequence encoding a polypeptide of the invention that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code (e.g., as set forth in Table 1, or as is commonly available in the art) as
applied to the nucleic acid sequence encoding a hemagglutinin or a neuraminidase polypeptide of the invention. All such variations of every nucleic acid herein are specifically provided and described by consideration of the sequence in combination with the genetic code. One of skill is fully able to make these silent substitutions using the methods herein.

Conservative variations

[0165] Owing to the degeneracy of the genetic code, “silent substitutions” (i.e., substitutions in a nucleic acid sequence which do not result in an alteration in an encoded polypeptide) are an implied feature of every nucleic acid sequence of the invention which encodes an amino acid. Similarly, “conservative amino acid substitutions,” in one or a few amino acids in an amino acid sequence are substituted with different amino acids with highly similar properties, are also readily identified as being highly similar to a disclosed construct such as those herein. Such conservative variations of each disclosed sequence are a feature of the present invention.

[0166] “Conservative variations” of a particular nucleic acid sequence refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or, where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences, see, Table 2 below. One of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 4%, 3%, 2% or 1%) in an encoded sequence are “conservatively modified variations” where the alterations result in the deletion of an amino acid, addition of an amino acid, or substitution of an amino acid with a chemically similar amino acid. Thus, “conservative variations” of a listed polypeptide sequence of the present invention include substitutions of a small percentage, typically less than 5%, more typically less than 4%, 3%, 2% or 1%, of the amino acids of the polypeptide sequence, with a conservatively selected amino acid of the same conservative substitution group. Finally, the addition of sequences which do not alter the encoded activity of a nucleic acid molecule, such as the addition of a non-functional sequence, is a conservative variation of the basic nucleic acid.

[0167] Table 2 -- Conservative Substitution Groups

<table>
<thead>
<tr>
<th></th>
<th>Alanine (A)</th>
<th>Serine (S)</th>
<th>Threonine (T)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

59
Unique Polypeptide and Polynucleotide Subsequences

[0168] In one aspect, the invention provides a nucleic acid which comprises a unique subsequence in a nucleic acid selected from the sequence of HA and NA molecules disclosed herein, e.g., SEQ ID NO: 1-10. The unique subsequence is unique as compared to a nucleic acids corresponding to nucleic acids such as, e.g., those found in GenBank or other similar public databases at the time of filing. Alignment can be performed using, e.g., BLAST set to default parameters. Any unique subsequence is useful, e.g., as a probe to identify the nucleic acids of the invention. See, above.

[0169] Similarly, the invention includes a polypeptide which comprises a unique subsequence in a polypeptide selected from the sequence of HA and NA molecules disclosed herein, e.g., SEQ ID NO: 11-20. Here, the unique subsequence is unique as compared to a polypeptide corresponding to, e.g., the amino acid corresponding to polynucleotide sequences found in, e.g., GenBank or other similar public databases at the time of filing.

[0170] The invention also provides for target nucleic acids which hybridize under stringent conditions to a unique coding oligonucleotide which encodes a unique subsequence in a polypeptide selected from the sequences of HA and NA molecules of the invention wherein the unique subsequence is unique as compared to a polypeptide corresponding to any of the control polypeptides (sequences of, e.g., the nucleic acids corresponding to those found in, e.g., GenBank or other similar public databases at the time of filing). Unique sequences are determined as noted above.

Sequence comparison, identity, and homology

[0171] The terms “identical” or percent “identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that
are the same or have a specified percentage of amino acid residues or nucleotides that are
the same, when compared and aligned for maximum correspondence, as measured using
one of the sequence comparison algorithms described below (or other algorithms available
to persons of skill) or by visual inspection.

[0172] The phrase “substantially identical,” in the context of two nucleic acids or
polypeptides (e.g., DNAs encoding a HA or NA molecule, or the amino acid sequence of a
HA or NA molecule) refers to two or more sequences or subsequences that have at least
about 90%, preferably 91%, most preferably 92%, 93%, 94%, 95%, 96%, 97%, 98%,
98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or more
nucleotide or amino acid residue identity, when compared and aligned for maximum
 correspondence, as measured using a sequence comparison algorithm or by visual
inspection. Such “substantially identical” sequences are typically considered to be
“homologous,” without reference to actual ancestry. Preferably, “substantial identity” exists
over a region of the amino acid sequences that is at least about 200 residues in length, more
preferably over a region of at least about 250 residues, and most preferably the sequences
are substantially identical over at least about 300 residues, 350 residues, 400 residues, 425
residues, 450 residues, 475 residues, 480 residues, 490 residues, 495 residues, 499 residues,
500 residues, 502 residues, 559 residues, 565 residues, or 566 residues, or over the full
length of the two sequences to be compared.

[0173] For sequence comparison and homology determination, typically one
sequence acts as a reference sequence to which test sequences are compared. When using a
sequence comparison algorithm, test and reference sequences are input into a computer,
subsequence coordinates are designated, if necessary, and sequence algorithm program
parameters are designated. The sequence comparison algorithm then calculates the percent
sequence identity for the test sequence(s) relative to the reference sequence, based on the
designated program parameters.

[0174] Optimal alignment of sequences for comparison can be conducted, e.g., by
the local homology algorithm of Smith & Waterman, Adv Appl Math 2:482 (1981), by the
homology alignment algorithm of Needleman & Wunsch, J Mol Biol 48:443 (1970), by the
search for similarity method of Pearson & Lipman, Proc Natl Acad Sci USA 85:2444
(1988), by computerized implementations of algorithms such as GAP, BESTFIT, FASTA,
and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575
Science Dr., Madison, WI, or by visual inspection (see generally, Ausubel et al., supra).

[0175] One example of an algorithm that is suitable for determining percent
sequence identity and sequence similarity is the BLAST algorithm, which is described in
is publicly available through the National Center for Biotechnology Information
(www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence
pairs (HSPs) by identifying short words of length W in the query sequence, which either
match or satisfy some positive-valued threshold score T when aligned with a word of the
same length in a database sequence. T is referred to as the neighborhood word score
threshold (see, Altschul et al., supra). These initial neighborhood word hits act as seeds for
initiating searches to find longer HSPs containing them. The word hits are then extended in
both directions along each sequence for as far as the cumulative alignment score can be
increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters
M (reward score for a pair of matching residues; always > 0) and N (penalty score for
mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to
calculate the cumulative score. Extension of the word hits in each direction are halted
when: the cumulative alignment score falls off by the quantity X from its maximum
achieved value; the cumulative score goes to zero or below, due to the accumulation of one
or more negative-scoring residue alignments; or the end of either sequence is reached. The
BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the
alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength
(W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both
strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W)
of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see, Henikoff &

[0176] In addition to calculating percent sequence identity, the BLAST algorithm
also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin
& Altschul, Proc Natl Acad Sci USA 90:5873-5787 (1993)). One measure of similarity
provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an
indication of the probability by which a match between two nucleotide or amino acid
sequences would occur by chance. For example, a nucleic acid is considered similar to a
reference sequence if the smallest sum probability in a comparison of the test nucleic acid to
the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and
most preferably less than about 0.001.

[0177] Another example of a useful sequence alignment algorithm is PILEUP.

5 PILEUP creates a multiple sequence alignment from a group of related sequences using
progressive, pairwise alignments. It can also plot a tree showing the clustering relationships
used to create the alignment. PILEUP uses a simplification of the progressive alignment
method of Feng & Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to
the method described by Higgins & Sharp (1989) CABIOS:151-153. The program can
align, e.g., up to 300 sequences of a maximum length of 5,000 letters. The multiple
alignment procedure begins with the pairwise alignment of the two most similar sequences,
producing a cluster of two aligned sequences. This cluster can then be aligned to the next
most related sequence or cluster of aligned sequences. Two clusters of sequences can be
aligned by a simple extension of the pairwise alignment of two individual sequences. The
final alignment is achieved by a series of progressive, pairwise alignments. The program
can also be used to plot a dendogram or tree representation of clustering relationships. The
program is run by designating specific sequences and their amino acid or nucleotide
coordinates for regions of sequence comparison.

[0178] An additional example of an algorithm that is suitable for multiple DNA, or
amino acid, sequence alignments is the CLUSTALW program (Thompson, J. D. et al.
comparisons between groups of sequences and assembles them into a multiple alignment
based on homology. Gap open and Gap extension penalties can be, e.g., 10 and 0.05
respectively. For amino acid alignments, the BLOSUM algorithm can be used as a protein
10915-10919.

DIGITAL SYSTEMS

[0179] The present invention provides digital systems, e.g., computers, computer
readable media and integrated systems comprising character strings corresponding to the
sequence information herein for the nucleic acids and isolated or recombinant polypeptides
herein, including, e.g., the sequences shown herein, and the various silent substitutions and
conservative substitutions thereof. Integrated systems can further include, e.g., gene synthesis equipment for making genes corresponding to the character strings.

Various methods known in the art can be used to detect homology or similarity between different character strings (see, above), or can be used to perform other desirable functions such as to control output files, provide the basis for making presentations of information including the sequences and the like. Examples include BLAST, discussed supra. Computer systems of the invention can include such programs, e.g., in conjunction with one or more data file or data base comprising a sequence as noted herein.

Thus, different types of homology and similarity of various stringency and length between various HA or NA sequences or fragments, etc. can be detected and recognized in the integrated systems herein. For example, many homology determination methods have been designed for comparative analysis of sequences of biopolymers, for spell-checking in word processing, and for data retrieval from various databases. With an understanding of double-helix pair-wise complement interactions among 4 principal nucleobases in natural polynucleotides, models that simulate annealing of complementary homologous polynucleotide strings can also be used as a foundation of sequence alignment or other operations typically performed on the character strings corresponding to the sequences herein (e.g., word-processing manipulations, construction of figures comprising sequence or subsequence character strings, output tables, etc.).

Thus, standard desktop applications such as word processing software (e.g., Microsoft Word™ or Corel WordPerfect™) and database software (e.g., spreadsheet software such as Microsoft Excel™, Corel Quattro Pro™, or database programs such as Microsoft Access™, Paradox™, GeneWorks™, or MacVector™ or other similar programs) can be adapted to the present invention by inputting a character string corresponding to one or more polynucleotides and polypeptides of the invention (either nucleic acids or proteins, or both). For example, a system of the invention can include the foregoing software having the appropriate character string information, e.g., used in conjunction with a user interface (e.g., a GUI in a standard operating system such as a Windows, Macintosh or LINUX system) to manipulate strings of characters corresponding to the sequences herein. As noted, specialized alignment programs such as BLAST can also be incorporated into the
systems of the invention for alignment of nucleic acids or proteins (or corresponding character strings).

[0183] Systems in the present invention typically include a digital computer with data sets entered into the software system comprising any of the sequences herein. The computer can be, e.g., a PC (Intel x86 or Pentium chip-compatible DOS™, OS2™ WINDOWS™ WINDOWSNT™, WINDOWS95™, WINDOWS2000™, WINDOWS98™, LINUX based machine, a MACINTOSH™, Power PC, or a UNIX based (e.g., SUN™ work station) machine) or other commercially available computer that is known to one of skill. Software for aligning or otherwise manipulating sequences is available, or can easily be constructed by one of skill using a standard programming language such as Visualbasic, PERL, Fortran, Basic, Java, or the like.

[0184] Any controller or computer optionally includes a monitor which is often a cathode ray tube ("CRT") display, a flat panel display (e.g., active matrix liquid crystal display, liquid crystal display), or others. Computer circuitry is often placed in a box which includes numerous integrated circuit chips, such as a microprocessor, memory, interface circuits, and others. The box also optionally includes a hard disk drive, a floppy disk drive, a high capacity removable drive such as a writeable CD-ROM, and other common peripheral elements. Inputting devices such as a keyboard or mouse optionally provide for input from a user and for user selection of sequences to be compared or otherwise manipulated in the relevant computer system.

[0185] The computer typically includes appropriate software for receiving user instructions, either in the form of user input into a set parameter fields, e.g., in a GUI, or in the form of preprogrammed instructions, e.g., preprogrammed for a variety of different specific operations. The software then converts these instructions to appropriate language for instructing the operation, e.g., of appropriate mechanisms or transport controllers to carry out the desired operation. The software can also include output elements for controlling nucleic acid synthesis (e.g., based upon a sequence or an alignment of sequences herein), comparisons of samples for differential gene expression, or other operations.

KITS AND REAGENTS

[0186] The present invention is optionally provided to a user as a kit. For example, a kit of the invention contains one or more nucleic acid, polypeptide, antibody, or cell line
described herein (e.g., comprising, or with, a HA and/or NA molecule of the invention). The kit can contain a diagnostic nucleic acid or polypeptide, e.g., antibody, probe set, e.g., as a cDNA micro-array packaged in a suitable container, or other nucleic acid such as one or more expression vector. The kit can also further comprise, one or more additional reagents, e.g., substrates, labels, primers, for labeling expression products, tubes and/or other accessories, reagents for collecting samples, buffers, hybridization chambers, cover slips, etc. The kit optionally further comprises an instruction set or user manual detailing preferred methods of using the kit components for discovery or application of diagnostic sets, etc.

When used according to the instructions, the kit can be used, e.g., for evaluating a disease state or condition, for evaluating effects of a pharmaceutical agent or other treatment intervention on progression of a disease state or condition in a cell or organism, or for use as a vaccine, etc.

In an additional aspect, the present invention provides system kits embodying the methods, composition, systems and apparatus herein. System kits of the invention optionally comprise one or more of the following: (1) an apparatus, system, system component or apparatus component; (2) instructions for practicing methods described herein, and/or for operating the apparatus or apparatus components herein and/or for using the compositions herein. In a further aspect, the present invention provides for the use of any apparatus, apparatus component, composition or kit herein, for the practice of any method or assay herein, and/or for the use of any apparatus or kit to practice any assay or method herein.

Additionally, the kits can include one or more translation system as noted above (e.g., a cell) with appropriate packaging material, containers for holding the components of the kit, instructional materials for practicing the methods herein and/or the like. Similarly, products of the translation systems (e.g., proteins such as HA and/or NA molecules) can be provided in kit form, e.g., with containers for holding the components of the kit, instructional materials for practicing the methods herein and/or the like.

To facilitate use of the methods and compositions of the invention, any of the vaccine components and/or compositions, e.g., reassorted virus in allantoic fluid, etc., and additional components, such as, buffer, cells, culture medium, useful for packaging and
infection of influenza viruses for experimental or therapeutic vaccine purposes, can be
packaged in the form of a kit. Typically, the kit contains, in addition to the above
components, additional materials which can include, e.g., instructions for performing the
methods of the invention, packaging material, and a container.

EXAMPLES
Construction and Analysis of H5N1 ca Viruses and Vaccines

Various sequences herein comprising H5N1 HA/NA sequences were used to
create influenza viruses and vaccines. The HA sequences in such vaccines were altered
from wild-type by removal of the polybasic cleavage site within the HA. The HA/NA
sequences were reassorted (in a 6:2 reassortment) with A/AA/6/60 (an att, ca virus, see
above).

Three strains of H5N1 influenza were used in this example:
A/VN/1203/2004, A/HK/491/97, and A/HK/213/2003. Such strains are also referred to
within this example as the '97, '03, and '04 strains based on their year designations. The
percent similarity of the HA genes of such three strains is 95-96%. Figure 1 illustrates
modification of the polybasic cleavage site of an exemplary HA sequence, the '04 HA
sequences, used to construct the viruses/vaccines. As stated previously, various
embodiments of the invention comprise sequences which have differing regions of the
polybasic cleavage site removed. See above.

As stated, the modified H5N1 sequences (i.e., the modified '97, '03, and '04
genes) were used to construct 6:2 reassortant viruses with A/AA/6/60. It will be
appreciated, and is pointed out elsewhere herein, that other desirable backbones could also
have been used (e.g., PR8, etc.).

In the 6:2 reassortants of this example, the HA and NA gene sequences were
derived from the wild type parent virus and the remaining genes were characterized by
sequence analysis as derived from the A/AA/6/60 ca parent virus. The reassorted viruses
replicated to 8.0-8.5 log_{10} TCID_{50} in eggs. However, it will be appreciated that other
embodiments wherein the log_{10} TCID_{50} comprises from about 7.0 to about 9.0, from about
7.5-8.5, or from about 8.0-8.5 are also claimed within the invention. The cleavability of the
modified HA in the constructed viruses by endogenous proteases was restricted in vitro and
the viruses were dependent on trypsin (e.g., from about 0.1 ug/ml to about 1.0 ug/ml) for
growth. The constructed viruses were temperature sensitive in vitro.

[0195] The H5N1 ca reassortant viruses (having the modified '97, '03, or '04 HA
genomes) were not highly pathogenic for chickens. For example, when 4-week-old SPF white
Plymouth Rock chickens were inoculated intravenously with a 1:10 dilution of stock virus
\((10^{8.75} \text{ TCID}_{50}/\text{ml})\) and observed for 10 days, it was observed that 8 out of 8 chickens died
within 1-2 days when wild-type '97, '03, and '04 H5N1 were used, while 0 of 8 chickens
died when the H5N1 ca reassortant viruses were used. As can be seen in Figure 2, the
intranasally administered H5N1 ca reassortant viruses did not replicate in chickens.

[0196] The H5N1/AA ca reassortants were also not lethal for mice. See Figure 3,
which also shows the TCID_{50} for the H5N1 wild-type strains. Figure 4 shows that the 1997
and 2004 H5N1 ca reassortant viruses were restricted in replication in mice. Figure 5,
shows that the H5N1 ca reassorted viruses are restricted in replication in lungs of mice.

[0197] A comparison of the serum HAI antibody titers elicited in mice following a
single intranasal dose of vaccine (2003 ca as compared against 2003 wild-type), is shown in
Figure 6.

Figure 7 shows similar measurements, but using serum neutralizing antibody titers.

[0198] Figure 8 displays that the H5N1 ca reassortant viruses protect mice from
lethal challenge with 50, 500, or 5,000 LD_{50} of wild-type H5N1 virus. Figure 9 shows the
efficacy of protection from pulmonary replication of homologous and heterologous H5N1
challenge viruses in mice. As can be seen, the ca reassortants replicated less well than the
wild-type viruses did. Figure 10 shows related data using upper respiratory tracts of mice.
Those of skill in the art will be familiar with homologous and heterologous challenges (e.g.,
testing whether 2003 vaccine protects against a 2003 wild-type challenge (homologous) or
whether a 2003 vaccine protects against a 1997 wild-type challenge (heterologous), etc.).

[0199] Figure 11 shows efficacy of protection conferred by 2004 H5N1 ca vaccine
against high dose \((10^5 \text{ TCID}_{50})\) challenge with homologous or heterologous H5N1 wild-type
viruses in mice. Figure 12 shows efficacy of protection conferred by 1997 and 2003 H5N1
ca vaccines against high dose \((10^5 \text{ TCID}_{50})\) challenge with homologous or heterologous
H5N1 wild-type viruses in mice. Figure 13 shows efficacy of protection conferred by 2004
H5N1 ca vaccine against low or high doses of homologous H5N1 wild-type virus challenge
in mice. Figures 11-13 demonstrate that the tested vaccines could protect against other related viruses.

[0200] The current example demonstrates several points concerning exemplary H5N1 ca reassortant viruses/vaccines of the invention. The modified ca reassortant '97, '03, and '04 viruses were shown to have in vitro ts phenotype, loss of pathogenicity in chickens and attenuation in mice. It is expected that attenuation is also present in ferrets. Efficacy of protection and cross-protection against lethal challenge and systemic spread with wild-type viruses in mice was also shown. Efficacy of protection and cross-protections against replication of wild-type challenge viruses in the respiratory tract of mice is also expected.

[0201] It is contemplated to use these (and similar) viruses/vaccines to determine whether immunogenicity and efficacy is improved following 2 doses of vaccine; to assess immunogenicity in non-human primates; to assess attenuation and vaccine efficacy in ferrets; to determine the contribution of humoral and cellular immunity to observed efficacy of the produced vaccines in mice; to determine which residues of the 2003 HA contribute to enhanced immunogenicity and introduce them into 1997 and 2004 HAs; and to determine the effects of deleting the multibasic amino acid cleavage site and of the gene constellation.

[0202] While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. For example, all the techniques and apparatus described above may be used in various combinations. All publications, patents, patent applications, or other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document were individually indicated to be incorporated by reference for all purposes. In particular, U.S. provisional application nos. 60/574,553 filed May 24, 2004 and 60/657,554, filed February 28, 2005, are incorporated herein in their entirety for all purposes.
SEQUENCES

A/Vietnam/1203/04

Nucleotide Sequence of A/Vietnam/1203/04 H5 (SEQ ID NO:1)

Entire molecule length: 1767 nt

```
1 agcaaaagca ggggttcaat ctgtcaaat gagaataaata tggctctcttt
51 ttgcaatagt cagctctgtaa aaaaatgtac agatggtcat tggattcatt
101 gcaaaacaact gagaagagaag tggacaca ataatggaga aagagcttaac
151 tgattacacat gaccaagaacct cagctgaaga aacaccaacga gagaagcttt
201 gcggagttag gggctggttcc ccttatttt ttggatttttt cacccctagtta
251 ggattggtcgc tgggagccag aacaggaagtctgc aatcatactcattcattac
301 atatgtgtagc cggctgtcag tagtttaggtg tggctgtagaatcaggttctc
351 gcggagttggt gggggttagt ggggggaatt ggctgtagagcagcagctgta
401 ttgcaatagtaa ggggtgagtg gcccaacgac aagcagtaacag caggtgtcgg
451 tttacaacat gtcagagctg gggggtgagt ggcagtcgcattatgaagctgta
501 tggctggaga cggggttttt ggtgcgtactgc cctttgggaga gggggagtttt
```

Entire molecule length: 1767 nt

Amino acid sequence of A/Vietnam/1203/04 H5 (SEQ ID NO:11)

Entire molecule length: 564 aa

```
1 mekivllfai valvksdqic igyhannste qvdtmeknv tvthaqdlie
51 kkhngklcdl dgyvktliird cswqvgwlgp pmcdrefinyp esylivekan
101 pvndlcypgd fndyeelkhk lsrinhfekqi qiiipksswss heaslgvssa
```
Nucleotide Sequence of A/Vietnam/1203/04 N1 (SEQ ID NO: 2)

Entire molecule length: 1398 nt

15

1 agcaaaagca ggagttccaa atgaatccaa atcgagaatg aataaccatc
51 ggttctaatct ttgatgttaa cgggaagatc taaaatcag
100 gaaacagtac tcacataggg tcaagctcac aactcagcga ggaatcacc
151 accaatcagta accaatcagc aactaatatg ctacctgctg gaaagcttg
200 gtcctcagtag aactcagtag ggcagttgg cctccatcag ttaaaggtaag
250 gctgctagttg aactcagtag ggcagttgg cacatctgac ttaaaggtaag
300 gctgctagttg aactcagtag ggcagttgg cacatctgac ttaaaggtaag
350 gctgctagttg aactcagtag ggcagttgg cacatctgac ttaaaggtaag
400 gctgctagttg aactcagtag ggcagttgg cacatctgac ttaaaggtaag
450 gctgctagttg aactcagtag ggcagttgg cacatctgac ttaaaggtaag

Amino acid sequence of A/Vietnam/1203/04 N1 (SEQ ID NO: 12)

Entire molecule length: 449 aa

1 mnpngkiiit geicmtgtyi slnlqignni siwsvshisht gnqhsepis
51 ntnfltekav asvyklagns lcepngwvy skdmsirig ksgdfvirep
101 fiscshlecr tffltgall ndkhsngtvk dresphrlms cpvgeaspy
151 nsfesvaws asachdgtsw ltgisispdn gavaklyknj iitditkswr
A/Hong Kong/213/03
Nucleotide Sequence of A/Hong Kong/213/03 H5 (SEQ ID NO: 3)

Entire molecule length: 1767 nt

Entire molecule length: 564 aa

Amino acid sequence of A/Hong Kong/213/03 H5 (SEQ ID NO: 13)
Nucleotide Sequence of A/Hong Kong/213/03 N1 (SEQ ID NO: 4)

Entire molecule length: 1458 nt

Amino acid sequence of A/Hong Kong/213/03 N1 (SEQ ID NO: 14)
Entire molecule length: 469 aa

1 mpnpqkittg sisicmvgiv slmlqignii siwvshsiqt gnqhqaepcn
51 qsityennnt vivngyvnis ntnfltekav asvvlagnns lcpisgwavv
10 skdngirigs kgdvgvirep fischlecre tffltggall ndkhsngtvk
51 drrphrtlmes cpgveaspyp nsrfesvaws asachdgtsw tltigsgpdpn
20 gavvalvkyng ittdtiksw nrmirmtqese cacvngscft vmtdgpsnqg
25 asyklfriek gkvks.statistics aptnhtugecs cypradgletc vcrdmwhgsn
30 rpwvesfnqnl eyrigycics vgfdnpnpnd gtscgcpvsp kgaygikgfs
35 fkyngnywv rtksbnsrgq femiwdpnpgw tgdnsfsvk qdkidltwds
40 gysgsfvyqhp eltgdlicpr cfwvelirgr pkstiwtsng ssisfcgvns
45 dtvwgsdpgd aelpftidk

15 A/Hong Kong/491/97 (HA) + A/Hong Kong/486/97 (NA)
Nucleotide Sequence of A/Hong Kong/491/97 H5  (SEQ ID NO: 5)
Entire molecule length: 1767 nt

1 aggcaaaagca ggggtataat ctcgtcactly ggagaaatag tgtctcttccc
20 ttcgacacagt cagcccttgtt aaaaagtcac agaaaagctag tggtaacat
10 gcacaaactg agaggagacac atataacaac catctctcgtt gtcgctcttc
15 ttcgctcat gccgcttcct ggagagcttt cggagctctt tcctgccacc
20 ttcgctcttc atagttgaga aggccagctcc agcccaagtac cttgctttac
25 caccgagatg cagaccgatt gtaaagagaa gtaagacaata cacgacacaat
30 accaatttag gtaaacaaga gaggctcacc caatcaacc cagcagactc
35 gctgtgctcc agaagaagag atgccgctatt gcgctgctct ttcgacacagt
40 ggcctgcatt cccctgctgt ggtgtgcaca atctcaacc cagccagactc
45 acgcaagatg tgtctctcat cgtgctcatt gcgctgctatt gcgctgctatt
50 agatccttgag gtcgctgttt gctggcacac attaccccag ccctgctatt
55 ctgctgtctg gacccagctatt gcgctgctatt gcgctgctatt gcgctgctatt
60 cggctcatt gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
65 ctcggtgcgt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
70 gacccagctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
75 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
80 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
85 ctcggtgcgt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
90 acgcaagatg tgtctctcat cgtgctcatt gcgctgctatt gcgctgctatt
95 aggctcattt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
100 acgcaagatg tgtctctcat cgtgctcatt gcgctgctatt gcgctgctatt
105 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
110 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
115 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
120 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
125 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
130 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
135 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
140 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
145 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
150 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
155 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
160 gtcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt gcgctgctatt
Amino acid sequence of A/Hong Kong/491/97 H5 (SEQ ID NO: 15)

Entire molecule length: 564 aa

Nucleotide Sequence of A/Hong Kong/486/97 N1 (SEQ ID NO: 6)

Entire molecule length: 1401 nt
Amino acid sequence of A/Hong Kong/486/97 N1 (SEQ ID NO: 16)
Entire molecule length: 450 aa

A/Hong Kong/491/97 (Ser211) (HA) + A/Hong Kong/486/97 (NA)
Nucleotide Sequence of A/Hong Kong/491/97 (Ser211) H5 (SEQ ID NO: 7)
Entire molecule length: 1767 nt
Amino acid sequence of A/Hong Kong/491/97 (Ser211) H5 (SEQ ID NO: 17)
Entire molecule length: 564 aa

Nucleotide Sequence of A/Hong Kong/486/97 N1 (SEQ ID NO: 8)
Entire molecule length: 1401 nt
1051 aaagcactag ttccaggagc ggtttgaaa tgatttggga tccaaatggg
1101 tggacccgaa cagacagctt cccttcggtt aaagcagaca tcatacgagat
1151 aactgattgg tcaggtatca ggggaaggct tatctcaatc ccgaactctga
1201 caggtatataa ttgcatgaga ccctgtcttc gggttgatg aaattacaggg
5
1251 aggccccaaag agaacaaaca ctggactagt ggaggcagta tacctctctg
1301 ttggtaataat ctgacacgct ttggtggttc ttggccacag ggtgctgagt
1351 tgccatacac cattgacaag tagttgttct aaaaaactcc ttgtttctac
1401 t

10

Amino acid sequence of A/Hong Kong/486/97 N1 (SEQ ID NO: 18)
Entire molecule length: 450 aa

1 mmpnqkiiti gsicmvvgii smlqiqnti svwvshiikt whpnqpepcn
51 qsinftyeqa aasvrlagns slcpisgwai yskndnsrigr skgdvfvire
101 pfischleic rtfllftgall lnkhsngtvc kdrspyr1tm lscpveaeps
151 ynsrfesvesassacnhgis wltigisgpd ngavavlnkyn giititiksw
201 rnmtrtqges eacvncsacv tfmtdgpsne qasykifkie kgvvvpvksvel
251 napnyyeeic scepdaegit cvcrdwhgs nrwpwfsdeqy leyqiygylcs
301 gvfgdsprrpn dgttsgcvps lngayvgkgf stkynvwi giltrksrss
351 gcemfwdpng wtetdssfl kqdliaitdw sgysgefipq pelgtlncmr
401 pcfwvelirg rpkektiws gssisfcgyn sdtvgspsd gaelpytidk

25 ca A/ck/Hong Kong/G9/97
Nucleotide sequence of ca A/ck/Hong Kong/G9/97 (SEQ ID NO: 9)
Entire molecule length: 1690 bp

1 ttaaccacac gagaqtaag ga gataactacc tataactata ctactagtac
51 taacagcaag caattgcaac aaaaatcgca tccgctacca atccaaacac
30 101 ttacacagaa ccctctcag tgcaacacaa aaaattgcttc tctgtacaca
151 tggccaaagaa ttgcttccca cagagcacaag tgggatcgtg tgggtacac
201 atctggtcag ccctctcttctt atctagatca gcaccattga aggactgtac
251 tatggtaccc tttctttcctt tagacattg tggagagag tattgtattct
301 cctcggtgca agaccacgtgt gttataatgg atgtgttacc cccgggaatt
35 101 taggaaaaact aagagagact ttagttatag ctgctgctcct gttctctac
401 caaagatcacc agatctcccttc agacacatac tgggtgctgt cttacaggtg
451 aacaacacaa gcaagtttcac cattctttctt attatttactt ataccggaag
50 101 ctgctatcag ccaaaatcact acacacagaa tgcacacaca caaagttggg
601 caacaggaag cagattgctt acacacggtt acacacacag caaagttggg
651 caacaggaag cagattgctt acacacggtt acacacacag caaagttggg
701 cttgctcact gctgctagag aagatatttag tattatttattt tgtgattgaa
751 accaggtcact cagattgctt acacacggtt acacacacag caaagttggg
801 ggtatggcct caacagtttc gggagagagc gcaagagaaat cttgacagac
45 851 gattttacac aatggttactg cttgtgctga gatactaagc gaaaggtggtg
901 cttatctacat actttggttac atccccata ccagttttctc gcattttggg
951 actgcacaaat cttgttggga cttataatgc cttggtttgt cttggttctg
1001 aggcaatgtgc cttgctgatct aagtagagga acatatttttt ggttgggtcg
1051 attccatcag gcaggtttgtct tttctctctt gccgtgtggt tttctctctt
50 1101 agcattcacaag agatatggtg gttggtataag ctgccagatag acaagtcaact
Amino acid sequence of ca A/ck/Hong Kong/G9/97 H9 (SEQ ID NO: 19)

Entire molecule: 558 aa

1  meariplitil  lvvtasnadk  icigyqstns  tetvdtlten  npvpvthakel  
51  lhthehngmlc  atnigrpiil  dtctiegliy  gnpscdilll  grewsyiver  
101  psavnmcyp  gnvenileelr  sffsasasyq  rigifpdtiw  nysysgtksa  
151  csdsfyrsmr  wltqknnyap  iqdaqtynnr  gksilfnweqi  nhpptdtaqt  
201  nlytrrdttqt  fkpqvirppl  vnpqgridry  ywsylkpgqt  
251  lrvrsngnli  apwyhgilsg  eshrigiktd  lnsqscvvcq  qtergqlntt  
301  lpfnhvsyka  fngtcpkyvyg  ksklavlqir  nvparsrql  fgaiagfieg  
351  gwsglvgavg  fgsqhnsqggv  giaadrdstq  raidkitskv  nnipvkmkg  
401  yelidhsef  venrlmnion  kiddgqidiw  aynaellvl  enqktldehd  
451  anvnlynkv  kralgename  dgkgcfehy  kcdgcmeti  rngtynrky  
501  keesrlerqk  iegvkleseg  tykiliyst  vasslviamg  faalfwams  
551  ngscrcni

Nucleotide sequence of ca A/ck/Hong Kong/G9/97 N2 (SEQ ID NO: 10)

Entire molecule: 1424 bp

1  aaatgaatcc  aaatcagga  ataatagcaa  ttttgtctgt  ttctcctaact  
35  atttgcatcaaa  tatgctctctt  catgcatgatt  gctatcttag  caacgcatact  
101  gacatacatc  ttccaacgca  ataatagcat  caactctctc  aatatcaagc  
151  tagtgccatg  tgaacaattc  ataatagaaaa  ggaacaataac  agagataagtg  
201  catttgaata  gtatctcttt  agaagagaa  attttgcttaa  aatttcagcaga  
251  ctaaatgagata  ttctctcata  aaccttttaaa  tgaatatgtt  ggtggtgctcg  
301  ttctctaggt  caaccaacaac  agtggctcata  gctatctctgcc  ctcaatctcg  
351  ccattagttg  aaacagttagt  tacatgctctgt  gttctcagag  gattcagaga  
401  atcgcaacgcg  tgtatacattat  tagatgtctg  gagctatcag  gctggtctctg  
451  ctctctctct  ctaaatctctct  ctaaatccttct  ccctttcttcttt  ctctctctct  
501  atatccagaa  gtttagatgtg  tgtgtctgctgg  caatctctct  ctatctctctt  
551  gccccttgtct  atatataaat  atggcagattat  atagatctagtt  ttccagtattat

79
951 gtgtgctcag gacctgttgg ccgacaccca agaaatgatg ataggtctag
1001 cagcagcaac tgccagagtc caataacgga gagaagggcc ccaggaatgaa
1051 aagggctggcc ctttgacaat ggaatgaca tttgtgtgag aagaacaactc
1101 aaaaaggttt ccgcttcaggg ttatgagactt ttcaaggtcattttgtgagttg
1151 gaccactgcct aattcccaaggt cagacataaa tagacaagctc ataggtgacga
1201 tgtgaaactct tgcctggtatt tgtgttatct ttctctgttga aggcgaaaagct
1251 tgcatacaac cgggtggtttta cgtggaaggttg ataagagagaa gacccaagagga
1301 gactaggggttg gttggtcactt taatagcgtatc cattgtatttt tgtggaacctt
1351 caggtaacctt tggaacagcc tcatggcccc tctgagggcaga tataaatattcc
1401 atgcctatat aagcttttgc aatatattag

Amino acid sequence of ca A/ck/Hong Kong/G9/97 N2 (SEQ ID NO: 20)
Entire molecule length: 469 aa

1 mnpnqkiiai gsvisltiatl cllmqliaaa ttmtltihfkqnt ecinssnnqv
51 vpcepiier niteivhlns ttlekeicpk vadyrnwskp gcqitgfapf
101 skdnsrlsa ggdiwtrtep yvscglgkcy qfalgggttl enkhsngtah
151 dtrphrtllm nlelgvpfhl atkqcviaawss sschdgkawl hvcvtdgddrn
20 atasiydgil lvdssigwsk nilrtqesec vcingtcavmv mtgdsasagra
251 dtrilfireg kiahisplsg saqhveecsc yprypevrcvc crdnwkgsnr
301 pvlyinmany sidssycscg lvdptprndd rssecondrp nnergapgvyk
351 gwafnngndi wmgrrtkkds rsgyefrvi ggwttansks qinrqrivds
401 dnssgysgif svecakcinr ccfyvelirgr pketrsvwwts nsiiivfgcgs
451 gtygtgswpd ganinfmpi
## SUMMARY OF SEQ ID NO DESIGNATIONS

<table>
<thead>
<tr>
<th>SEQ ID NO</th>
<th>HA or NA</th>
<th>STRAIN NAME</th>
<th>Amino Acid or Nucleotide</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEQ ID NO: 1</td>
<td>HA (H5)</td>
<td>ca A/Vietnam/1203/04</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 2</td>
<td>NA (N1)</td>
<td>ca A/Vietnam/1203/04</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 3</td>
<td>HA (H5)</td>
<td>ca A/Hong Kong/213/03</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 4</td>
<td>NA (N1)</td>
<td>ca A/Hong Kong/213/03</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 5</td>
<td>HA (H5)</td>
<td>ca A/Hong Kong/491/97</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 6</td>
<td>NA (N1)</td>
<td>ca A/Hong Kong/486/97</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 7</td>
<td>HA (H5)</td>
<td>ca A/Hong Kong/491/97 (Ser211)</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 8</td>
<td>NA (N1)</td>
<td>ca A/Hong Kong/486/97</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 9</td>
<td>HA (H9)</td>
<td>ca A/ck/Hong Kong/G9/97</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 10</td>
<td>NA (N2)</td>
<td>ca A/ck/Hong Kong/G9/97</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>SEQ ID NO: 11</td>
<td>HA (H5)</td>
<td>ca A/Vietnam/1203/04</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 12</td>
<td>NA (N1)</td>
<td>ca A/Vietnam/1203/04</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 13</td>
<td>HA (H5)</td>
<td>ca A/Hong Kong/213/03</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 14</td>
<td>NA (N1)</td>
<td>ca A/Hong Kong/213/03</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 15</td>
<td>HA (H5)</td>
<td>ca A/Hong Kong/491/97</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 16</td>
<td>NA (N1)</td>
<td>ca A/Hong Kong/486/97</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 17</td>
<td>HA (H5)</td>
<td>ca A/Hong Kong/491/97 (Ser211)</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 18</td>
<td>NA (N1)</td>
<td>ca A/Hong Kong/486/97</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 19</td>
<td>HA (H9)</td>
<td>ca A/ck/Hong Kong/G9/97</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>SEQ ID NO: 20</td>
<td>NA (N2)</td>
<td>ca A/ck/Hong Kong/G9/97</td>
<td>Amino Acid</td>
</tr>
</tbody>
</table>
CLAIMS

What is claimed is:

1. A 6:2 reassortment influenza virus, wherein said virus comprises 6 gene encoding regions from one or more donor viruses other than A/Ann Arbor/6/60 and 2 gene encoding regions that encode an HA and/or a NA polypeptides from a pandemic virus strain.

2. The 6:2 reassortment influenza virus of claim 1, wherein said donor virus has one or more of the following properties: temperature-sensitivity, cold-adaption, or attenuated.

3. The 6:2 reassortment influenza virus of claim 1, wherein said donor virus is PR8.

4. The 6:2 reassortment influenza virus of claim 1, wherein said donor virus is A/Leningrad/17.

5. An immunogenic composition comprising an immunologically effective amount of the recombinant influenza virus of claim 1.

6. An immunogenic composition comprising an immunologically effective amount of the recombinant influenza virus of claim 2.

7. An immunogenic composition comprising an immunologically effective amount of the recombinant influenza virus of claim 3.

8. An immunogenic composition comprising an immunologically effective amount of the recombinant influenza virus of claim 4.

9. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the recombinant influenza virus of claim 1 in a physiologically effective carrier.

10. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the recombinant influenza virus of claim 2 in a physiologically effective carrier.
11. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the recombinant influenza virus of claim 3 in a physiologically effective carrier.

12. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the recombinant influenza virus of claim 4 in a physiologically effective carrier.

13. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, a virus of claim 1 in an amount effective to produce an immunogenic response against the viral infection.

14. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, a virus of claim 3 in an amount effective to produce an immunogenic response against the viral infection.

15. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, a virus of claim 4 in an amount effective to produce an immunogenic response against the viral infection.

16. The method of claim 13, wherein said virus is killed or inactivated.

17. The method of claim 14, wherein said virus is killed or inactivated.

18. The method of claim 15, wherein said virus is killed or inactivated.

19. The immunogenic composition of claim 5, wherein the hemagglutinin comprises a modified polybasic cleavage site.

20. The immunogenic composition of claim 6, wherein the hemagglutinin comprises a modified polybasic cleavage site.

21. The immunogenic composition of claim 7, wherein the hemagglutinin comprises a modified polybasic cleavage site

22. The immunogenic composition of claim 8, wherein the hemagglutinin comprises a modified polybasic cleavage site.

23. The method of claim 9, wherein the subject is a human.
24. The method of claim 10, wherein the subject is a human.

25. The method of claim 11, wherein the subject is a human.


27. A live attenuated influenza vaccine comprising the composition of claim 8.

28. A method for producing influenza viruses in cell culture, the method comprising:

i) introducing into a population of host cells, which population of host cells is capable of supporting replication of influenza virus, a plurality of vectors comprising nucleic acid encoding:

(a) at least 6 internal genome segments of a first influenza strain, wherein the first influenza strain is not A/Ann Arbor/6/60; and, at least one genome segment encoding an immunogenic influenza surface antigen of a second influenza strain, wherein said second strain is a pandemic influenza strain; or

(b) at least 6 internal genome segments of a first influenza strain, wherein the first influenza strain is not A/Ann Arbor/6/60 and which influenza strain possesses one or more phenotypic attributes selected from the group consisting of: attenuated, cold adapted and temperature sensitive; and, at least one genome segment encoding an immunogenic influenza surface antigen of a second influenza strain, wherein said second strain is a pandemic influenza strain,

ii) culturing the population of host cells at a temperature less than or equal to 35°C; and,

iii) recovering a plurality of influenza viruses.

29. An immunogenic composition comprising an immunologically effective amount of the influenza virus of claim 28.

30. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the influenza virus of claim 28 in a physiologically effective carrier.
31. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual the immunogenic composition of claim 29.

32. A live attenuated influenza vaccine comprising the immunogenic composition of claim 29.

33. A split virus or killed virus vaccine comprising the immunogenic composition of claim 29.
VN/1203/2004 wildtype HA:
CCT CAA AGA GAG AGA AGA AGA AAA AAG AGA ▼ GGA TTA TTT
Pro Gln Arg Glu Arg Arg Arg Arg Lys Lys Arg Gly Leu Phe

Modified HA:
CCT CAA AGA GAG ACT _CGA ▼ GGA TTA TTT
Pro Gln Arg Glu Thr Arg Gly Leu Phe

▼ Site of cleavage of into HA1 and HA2 domains.

Residues that were mutagenized are underlined.
Figure 2

Virus isolation from swabs

<table>
<thead>
<tr>
<th>Virus</th>
<th>Mortality (dead/total)</th>
<th>Oropharyngeal</th>
<th>Cloacal</th>
<th>Antibody detected/total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td># shedding/total</td>
<td>Mean log_{10} titer (EID_{50})</td>
<td># shedding/total</td>
<td>Mean log_{10} titer (EID_{50})</td>
</tr>
<tr>
<td>1997, 2003 and 2004 H5N1 wt</td>
<td>8/8</td>
<td>8/8</td>
<td>&gt;6.3</td>
<td>8/8</td>
</tr>
<tr>
<td>1997, 2003 and 2004 H5N1 ca</td>
<td>0/8</td>
<td>0/8</td>
<td>&lt;0.9</td>
<td>0/8</td>
</tr>
</tbody>
</table>

Chickens were inoculated intranasally with 10^6 TCID_{50} of virus.
Figure 3
LD_{50} in mice

A/AA/6/60 ca          >10^7 TCID_{50}
A/HK/491/97            10^2 TCID_{50}
1997 H5N1/AA ca        >10^7 TCID_{50}
A/HK/213/2003          10^6 TCID_{50}
2003 H5N1/AA ca        >10^7 TCID_{50}
A/Vietnam/1203/2004    10^{0.4} TCID_{50}
2004 H5N1/AA ca        >10^7 TCID_{50}
Figure 4

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Virus</th>
<th>Average fold difference in titer over 3 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNGS</td>
<td>A/AA/6/60</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>1997 H5N1</td>
<td>501</td>
</tr>
<tr>
<td></td>
<td>2003 H5N1</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>2004 H5N1</td>
<td>430</td>
</tr>
<tr>
<td>NASAL</td>
<td>A/AA/6/60</td>
<td>32</td>
</tr>
<tr>
<td>TURBINATES</td>
<td>1997 H5N1</td>
<td>185</td>
</tr>
<tr>
<td></td>
<td>2003 H5N1</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td>2004 H5N1</td>
<td>100</td>
</tr>
</tbody>
</table>

$10^6$ TCID$_{50}$ of virus was administered intranasally and tissues were harvested on days 2, 3 or 4 post-infection. Virus titers are expressed as $\log_{10}$ TCID$_{50}$/g of tissue.
Figure 6

<table>
<thead>
<tr>
<th>Immunizing virus</th>
<th>Geometric mean serum HAI Ab titers against indicated virus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1997 wt</td>
</tr>
<tr>
<td>2003 ca</td>
<td>20</td>
</tr>
<tr>
<td>2003 wt</td>
<td>20</td>
</tr>
</tbody>
</table>

An undetectable titer is assigned a value of 20
Figure 7

<table>
<thead>
<tr>
<th>Immunizing virus</th>
<th>Geometric mean serum neutralizing Ab titers against indicated virus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1997 wt</td>
</tr>
<tr>
<td>2003 ca</td>
<td>10</td>
</tr>
<tr>
<td>2003 wt</td>
<td>10</td>
</tr>
</tbody>
</table>

An undetectable titer is assigned a value of 10
Figure 8

H5N1 1997 wt challenge

H5N1 2004 wt challenge

Days following administration of challenge virus
**Table: Mean reduction in titer in lungs following**

<table>
<thead>
<tr>
<th>Immunization</th>
<th>Homologous challenge</th>
<th>Heterologous H5N1 challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1997 wt</td>
</tr>
<tr>
<td>1997 ca</td>
<td>2.5</td>
<td>NA</td>
</tr>
<tr>
<td>2003 ca</td>
<td>&gt;5.8</td>
<td>2.3</td>
</tr>
<tr>
<td>2004 ca</td>
<td>2.0</td>
<td>1.4</td>
</tr>
</tbody>
</table>
Figure 10

<table>
<thead>
<tr>
<th>Immunization</th>
<th>Homologous challenge</th>
<th>Heterologous H5N1 challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1997 wt</td>
</tr>
<tr>
<td>1997 ca</td>
<td>4.3</td>
<td>NA</td>
</tr>
<tr>
<td>2003 ca</td>
<td>&gt;1.2</td>
<td>3.7</td>
</tr>
<tr>
<td>2004 ca</td>
<td>1.6</td>
<td>4.2</td>
</tr>
</tbody>
</table>
SEQUENCE LISTING

<110> MedImmune Vaccines, Inc et al.

<120> INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS

<130> FL260

<150> 60/574,553

<151> 2004-05-25

<150> 60/657,554

<151> 2005-02-28

<160> 20

<170> PatentIn version 3.3

<210> 1

<211> 1767

<212> DNA

<213> Influenza virus

<400> 1
agcagagaaac gggggttcat ctgtcacaat ggagaaataa gttgcttttt ttgcaatagt 60
cagtcctgtg aaaaagtcgtc atagttgcat tgggattacat gcaaacaact gcagagacga 120
ggtgacaca ataatggaa aagaacgttac tgggatccag gcaccaagaca tactggaaaa 180
gaaaccaac gggaagctct gcgtatcctag tgagttgaag ctccttaatttt tggagattgtgc 240
tagcgtagct ggattgtgtgtgc ttgggactcc ggttaattctg catctgatagc atggtcaacaagc 300
tgggattctg atagttgaga aggcccaact cgtcataagc gattgtctttc caacagttctcag 360
caatatatt gagaattag aacaccaattt accacttgg gagaatattt 420
gatatcggacctg cgcctgcttttt cggagtcctc ccctctctacc cactttttatc ctcctcttattttctcgctttttttccccgctttttttcttctcctcatc ccctctctacc ctgctttttcc ggcagttttg ggttaattgtgtg 960 540

tgagttgaag ctccttaattt tggagattgtgc ttgggactcc ggttaattctg catctgatagc atggtcaacaagc 540
tgagttgaag ctccttaattt tggagattgtgc ttgggactcc ggttaattctg catctgatagc atggtcaacaagc 540
tgagttgaag ctccttaattt tggagattgtgc ttgggactcc ggttaattctg catctgatagc atggtcaacaagc 540
tgagttgaag ctccttaattt tggagattgtgc ttgggactcc ggttaattctg catctgatagc atggtcaacaagc 540
tgagttgaag ctccttaattt tggagattgtgc ttgggactcc ggttaattctg catctgatagc atggtcaacaagc 540
ttttcatgac tcaaatgtca agaaccttta cgacaaagtc gcaacacagc tttagggataa 1440
tgcaaaagcg cctggtttaac accttctcgga tttctactac aataattgta atgaaatgtat 1500
ggaaatgta aagaaatggga cgtatgacta cccgcatata tcaagaagaag cgagactaa 1560
aagagagaa ataagttggag taaaatttga atcaataagga atttaccaaa tactgtcatt 1620
tttacctcaa gttgctggtt cctctagcact ggcaactatg gtagctgtggtc tatccttatg 1680
gattgctgcc aatggttctgct tacaatgcag aatattcatt taaaatttgg agttcagatt 1740
gattaataa acacccttgtt ttctact 1767

<210> 2
<211> 1398
<212> DNA
<213> Influenza virus

<400> 2
agcacaagca ggagtcacaa atgaaatccaa atcagaagat aataaccatc gggcatacctct 60
gtatgcttac cggagtaaatgt tacaatttgg gaaacattgct caaatatggg 120
tcaagtcacag aatttacacac ccaccactga acaccacagc aataactaat 180
ttcctactga gaaagctgtg gtagctgtaa aatgagccg gcaagtcatct ttttgcccca 240
ttaccaggaag ggtgtgtatac atgatgacaa acagttataag gatcgtgttctt aaggggattg 300
tgttactttatat aagagctgcc gpacctctcat cttctgccact ggaagctgaga actttttttttt 360
tgacactcgg acgccttgctg aatgacaagc actcccaatg gactgtcaca gacagaagcc 420
tccacagaca ataatgagtt gtctccccgtg gtagcgttcc cttcccccatat aactcaagct 480
ttngtctctgt tcgttctgcc gacagtgctct gacctcagtt caccagtgtt ggagatccttg 540
gaattcttgttg cccagaatat ggcgctgtgg tttgattgcta atacaatggc atattaacag 600
acacatcaag gattgccagg aacaacacat tcgaagacta agaggtcggg atgtcgcttgtg 660
ataatggcota tgcctcttact gtaatgcagt actggcctaaag gcataccaga ataatgctgctc 720
agattcttccaa aatggaaaaa gggagattgg ttaaatcact cgaatgtgat gctctcaatt 780
atacactatga ggaatgtcctc ttgttcttctct atgccgggaga aatcactatgt gttgctcagg 840
ataatggcota tgcctcctatt gggcctgaag tttctcttcc taaaattttg gatgtcaca 900
taggataatat atgcagctggga gtttccggag acaatccacgc ccctaacatg ggaagcatgta 960
gttggtctcc ggctgcctct tacaatgcat gcaccggcaat aggggtaataa aaggggttcc tttctaatacg 1020
gcaatggtgt cttgatcgccg agaacccaaa gcagcaattt caggagccgg tttgaatgta 1080
tttggggattc aaagttgtggt actggaaccgc actgtagccttt ctcagtgcaaa caagatattc 1140
tagcataaact gtagttgtcca ggtatatagc ggagtttcttg ccaagcatcga gcaactcag 1200
gactagattg catagactcct ttgttctgg gttgagttgt cagagggcgg cccaaagaga 1260
gcaatatttgc gactagttgg agcacatatc tttttgtggt ttagaattag gacactgtggt 1320
gttggtcttg gcacagcagt gctgagttgc ctcctcactct gcaagattgt gttgttccaa 1380
aaacactctttg ttctcact 1398
<210> 3
<211> 1767
<212> DNA
<213> Influenza virus

<400> 3
agcaaaagca ggggattcct ctgtcaaat gagaagaaata tggcttcttt ttgcaatagt 60
cagtcttgtt aaaaagttgac agattgtcct tgtttaccat ggcaacaact gcagagaga 120
ggtgacaca ataatgggaga aagacggtcct tgtacccata gccaaagaca tactggaara 180
gacacacaa gggagactcct ggcgattcata tggagttgaact cctcttaaatt tgagagattg 240
tagtttagct gattgtgatc atggtctgaa ctaattcacta ctattcatttt cagggattt 300
taggtcttacc atgtggagaga agggaatcctc cttcgctctc agggcgatt 360
cacacagactg aagaacttgga aaaacctattt gagacgagatc aaccattttt agagagatttca 420
gatcatctcag aaaaagctttgg ctgggagcctg tggacaagccttt tggagtgggt gttgctcgag 480
ttcatacag aagaggctcttc ccttttcctcag gatgtgagttcag tggcttcatag aaaaaagac 540
tgctacacc aacaataaga ggggactcttc taatatacctc caagaagactc aggactacatttt 600
gttggggattt cacacccttc atggactgcctgc atggaccttc aggacgactc aggacggtcttc 660
cacctacattt tggagggcgag ttcctggtgag atggaggtttaa aacaacgac 720
tagatcagaa gaaaaacggccttc aaatgagacg gaagggtggtgagttc aaaaatggac 780
gagaagactg caactccttc gaggagagaga aatattcattt cttgcggctcagat gatactcagtt 840
aaretttataa gagaagagctc cagcatattttt gaaaagtttg ggattaaaagttg tgaactgctta 900
cacacagactc caaatccttc ggaggctgtt gatactccttc atggagacttg aacactcctccttct 960
cctcttcctt aagactcggtaa ggccaaatg tggcaaatc caagattag ttcttggcac 1020
tggcgcgata atggcagacg ctcggaagaatt tggcttcctgc atgggattg 1080
tatagaggg gatagaggg cagttatcctcttt gttttggat agttgaccata atagcagagtt 1140
goaggaggtt ggagttcactg cagacaagttt atcccactcctt cagaaagagatc agttgacttt 1200
cataagagttt aatcgcgcactt gagaatttaa gaaactccttc ggagagatg gttggagaggt 1260
atatttataa atgggagcagta aataaaccagta aagatgggagc aagttgacccttcc 1320
agatgtcgc gctatttattg gttctctcctc gcggagagcagctg gaaatgagc aacattggt 1380
cattttaacttc ctcagacttta cggacactcttc ggcacactt caagatttgaa 1440
tgcaagagatc agttgatcctctct ttgctttcctc atggatcctt ctttactccca caaactcctttaa 1500
ggaaaagttg aagagagagttt gcagactctctc cccgcacgga tcgaagagatc caagactcta 1560
aagagagagttt cagttggtgaa atcaggtgata acaccacttc ggagagatg gttggagaggt 1620
ttatttattt gttctctcctc ctctgcacactt ggcacacttta cagagattgtgtaa 1680
gatgtgctctc cagtttggctc ttaatcaggtc aatatttggtaa atctgaatttattg 1740
gatgtgcttcc ctaagttggtt ttaatttgag taattttttgagtcagttttt 1767
Influenza virus

\[
gag\text{aaaagca}\ ggttt\text{aaaaa atg}\text{aatccaa atc}\text{agaagat aacaaccatt gatcaatct 60}
g\text{tggtaaat tgg}\text{aatgatt gtgc}\text{ttgatg tca}\text{aaatg tgg}\text{aagataatc tca}\text{aatatg g} 120
t\text{tagtctacct aatt\text{ccaaaca ggaatcaaac accaggctg}\text{a accatgcaat caaagcatt} 180
t\text{tcattatg aacaaacacc tgg}\text{ttaaacc agacatagtt ccaacacagc aat}\text{accatt} 240
t\text{tcattacg}\text{a aagagctg}\text{tg gcctcag}\text{taa cattaggcgg catttcatct tt}\text{ttgc}\text{ccc} 300
t\text{tagtgagtg gcctgtatac agt}\text{aaggaca agcgtataag aatcggttccc aagggggtg 360
t\text{ttg}\text{tggtaat aagagccgcg tccttctcat gc}\text{tccccacttt gc\text{aagctgac agatctttttt} 420
t\text{gacctcagg gcgccttgcgtaa aatca}\text{agacgc atctcaatgg gaccgtccaa gacagaagcc 480
t\text{ctccacagac attaagtgat tgc}\text{tccg} 540
t\text{tgagtgcttg tgc}\text{tttgtgctg gc}\text{caagtgcttt gctcag}\text{ttg cactagtg}\text{tgc g}\text{tgaagctatg 600
gaaggctgg cccagcaaat ggccgctgg ct}\text{tgatg}\text{ttg aatcaagc gatgatg}\text{tgaatata} 660
\text{acatcaatcg} 720
\text{tatgatgctct} 780
\text{aatgatgctct} 840
\text{atgatgggctcc} 900
\text{gatgagcagca ccttgttgcag cccagctatgc g} 1020
\text{atggaggggt ggtgcctc} 1080
\text{aggagcagcag c} 1140
\text{ttgggtctatat gatgctcagc} 1200
\text{agcagctatt cat} 1260
\text{gctctctgtgc ctc} 1320
\text{gctctgagttg tggctcc} 1380
\text{atataagc ccttgtttgctcc} 1440
\text{aagc}\text{aagcatcg tttctcaat} 1458
gacacacaac ggggaagctct gcgacctaaa tggagtgaag cctctgtattt tggagggattg 240
tagtgtagct ggtagctgcc tcggaaaccct tatgtgtgac gaattcatca atgtgcggga 300
atgtctttac atatgsgaa gggccagccc agccaaatgc cctctgttac ccaggaatttt 360
cacagactat gaagaactga aanacctatt gacgagaaata aaccatttgg agaaaaattca 420
gataatcccc aaaagttcctt ggtcttcaac tcgactgtcga ctcgggtctga gctcagcatg 480
tccataacctt gggaggtcct ccttttttcag aatatgtgta tgtgttcatca aaaaagacag 540
tagctaccean acaataaaaag ggagctcaca taatacaccac caagaaagtc ttttgggtact 600
gttggggtatt caccactcctg atgatgctgctc agagcagaca aggctctactc aaaaacccacac 660
cacctacacc t cct tgggca acatcacao ttgcctcag caaatagctc 720
tagacaaaaa gtaaaagggcg aatgaggggct acctgagttc tctttgaaag ctttaaaagcc 780
gaatgattgac acatttcctg aagtagaatag aatatcttcc ggtccagataatgacataca 840
aattgctagaa aagagggagact caacaattat gaaaaagtaata gtggagatag taactgc ta 900
caccaagtac caacattc cagagggtgctt accttctagt atgcacattc acaacataca 960
cccccttcacc atcggaggaat gccccaaataa tgtgaataca caacagattag tctttgcaac 1020
tggactcagaa aatcccccctc aatgagagac gcgaagactc tttgagctca tagaggttta 1080	tagagggga ggtaggagcc gatggcttat cttggtagatt atgtggtcat ggttgcacacet 1140
gcaggggagat ggtacgtctg cagacgctac aatccacacaa aagcataagt aatgggtcag 1200
caatagagtc aacctctgata ttaaacaatg gaacacttcc tttgagcgcgt tgggagaaggg 1260
atatataaac ttgagagga ggtagagaga ttaaacaataatggaatgac acggattcct 1320
agatgcttgg ctcttacatt gcgcagctctc gttttcctgt gaaatgtgga gaaactctta 1380
ccttctgtg ctaatgtctg aagaaccttta gcagaaggtgc gcagactacac gtagggtaaa 1440
tgcaagggag atctggaatag tgggtttcgta attctctacat aatgtgatac acgaatgtat 1500
ggaagaagtct aaaaaggcga cgtatgtcacta cccgcattat tcagagaaag caagacttaaa 1560
cagagagaa atagagtggct aaaatctgaa atcaatggaag aactaccaca aactgctcaat 1620
ttattacacaagtgggggttt ccctggtcatt gccacatcgat tgtgctgtgct tatattttatg 1680
gatggtctcc aatgtgacgtgta cacaatggcagt aattttgctaatggtttag agttcgatt 1740
gatgtttaaa aaccccttggt ttcttct 1767

<210> 6
<211> DNA
<213> Influenza virus

<400> 6
agcataaagca gggagtttata atgaatccaa atcagaaatatataacat ggtcataac 60
gcatggtagt tcggataatct agctttggtg tacaatttgtg aacacaata tctgatgtgct 120
tcagccacat aatatataact tggccacaaa accagctga accatgcaac caaagcaatct 180
atttttatcaac tgacggagct gcagcctcag tgcactttac ggcaaatgcc tctcttctgc 240
<210>  7
<211> DNA
<212> Influenza virus
<400>  7
agcaaaagca ggggtataat tgttctaaat ggagaaataa tgtgttctttc tgtcaacagt  60
cagcttggat taaaagttggt catagtgcat tgttttacttt gcaaccaactgtc gacagacag  120
agtttggata caaatgtaaca gcaagcaactt ttttttttttt gttcaagac  180
gacacacac ggggtgagct cctgcatgtc ggaagactgct gcgcgctgctt gagaagtttg  240
taggttgagt gcagttggat tgggaacctt tgttagagttt gattacagagt gattacagagt  300
atgttggatat aatagtgagg gcacagagct ttttttttttt ttttttttttt ttttttttttt  360
cagcaaacag cagctgtagc gggactgctgctgcacat gtatttttttttt ttttttttttt ttttttttttt  420

cacc tacatt tccgttgga a catcaac acat gaaccagaga ttgttttcag aaatagctac 720
tagacc ccaaa gtttaacccgc cagaggaag aatggagtcc ttctggacaa tttttaaagcc 780
gaattgcct atcattttgc agatgaatgg aataatttcat gctcagatg atgcatacaaa 840
aatgtcaag aaaggggacct caaacttat gaaagttgaa ttggaatag gtaactgca 900
ccacaagtgt caaacttcca tgcgggcaaat aacactctag tgcacttccc acaacataca 960
ccccctcacc atcgggggaat gcccccaataa tggtaatatca aacagattg tacctgcac 1020
tggcactcaga aatacccccc aagcagagac ggcagacact tttgagcata tagcaggtttt 1080	
tatataggg ggttgccgca gatgtgtaga tgttgtgttat gggtaaccat atagcaatga 1140
gcaggggagt gccagctctg cagaccaaga atccacacaaa aaggaatag atggagtac 1200
caaataagtc cacttagatca ttaaaacat gaaacactcag tttgagggcc tttggaagga 1260
atttaataac ttgggaaggga ggtatagagaatttaacaag aaaaatggga aagcattcct 1320
agatgtctgg actctaaagt cccaacctct ggttctcttg gaaatgcaga aacactctga 1380
ccttcacgac ccaatgcctta cagacaagtc gcaatcagtg ttatgggataa 1440
tgcaagggact cttggttaattt gtttgttcgga attctatcag aatgtctgata acgatgtat 1500
ggaaatctgta aaaaaagcggaa gtatgcacta cccgcagttat tcagaagaga caagactaaa 1560
cagaggagaa ataaatggag taaaattggag atcagtggga actacacaaaa actctgcaat 1620
tttttccaa ttggcagatgt cctccagacact gcacacactg atagctgtgc tatttttattga 1680
gatgtgtctcc aatggattcgt tacaatgcag aatgtgcatt taaatgttg agtctgatt 1740
gtagttaaa cacccttgtt tcttact 1767

<210> 8
<211> 1401
<212> DNA
<213> Influenza virus

<400> 8
agccaaagca ggagtttaaa atgaatccaa atcaagatgt aataacact gatcaactc 60
gcattgttgt tggataatct acgtttgtat tacaatttgg aacacataa tcgtatggg 120
tccagcccat aatatttacct tgcagccaaa accagccctga acatgcacaac aagacatca 180
atttttac cgctcagcctgt gcagtctcag tgcattgcag ggcacatcct cttctctgcc 240
cattagtgg tggccgtata tcagcaagac aacaattat aagaattgt tccaaagggg 300
atgttccccat tataagggaa ccatttcctat gcacgccccaa tttggaatgc agaacctt 360
tcttgacca agagccccat tggatgaaac agcatcctaa tgggccggtc aagacagg 420
gccccctatag aactttacag acgtgtctctg tgggttagcc cccctccccca tacaacccta 480
ggtttgacgtc tgggtctggg tcaacaagtg ctgagctgtt gttgcatgat gcaccacaa 540
ttggaatcc cgggccagat aatgagggcg tggctgttctt gaaatacaat ggccataactaa 660
cagacaccct caagagttgg aggaacaca cactgaggac gccagagtct gatgtgcac 660
gtgtaatggt ttctttgttctt acgttaatga cagagcggacc gatgtaatgaa cagccctcct 720
acaagatattt caagatagaa aaggggaggg tagtcaaatc agttgagttg aacgccctta 780
attatcatta cgaggaaatgc tctcttttatc ctgatgctgg cgaaatcaca tgtggtgtgca 840
gggataattg gcagttggtgg aaccgacctt gggtgtcttt caatcagaaat cttgagatatc 900
aataggata tatagcagt ggggtttttcg gagacagttcc aacgccccaat gatggggacag 960
gcagttggtgg tccagtgtct cttaaagagg cgtaagggat aaaaggggttt tcatattatat 1020
acggcaatttg tgtttgtgatc gggagaacca aagcactagt ttcccagggcg ggttttggaa 1080
tgattttgga tccaaatggc tggaggccaaa cagacaagtag ctcttctgtt aagcaagaca 1140
tcatagcgat aactgatttg tcggagaata gcggaggttt tattcaacat ccaagactga 1200
caggattaa atgcagcag ccttgtctctt ggtttgaact aacgacaggg cggcccaaaag 1260
agaaaaacact ctgagactgtg gggagacgtc ttttctttcttg tgggtgtaaat aagtgacactg 1320
tgggttggatct ttggcaggac ggtgtcgtag tggcataacat cattgacaag tagtttgttc 1380
aaaaaaaccttc ttgtttctac t 1401

<210> 9
<211> 1690
<212> DNA
<213> Influenza virus

<400> 9
ttaaccatct cagatgggaag caattaccct aataactata ctactagtag taacagcaag 60
caatgcagac aaaaatctgca tcggctacca atcacaacat tccacagaaa ccgtgacac 120
gctaaacaga aaacatgttc ctgtgacaca tgccaaagaa ttgctccaca cagacacaa 180
tgggatgtcg tgtgcaacaa atctgggaag tcctctttatt ctagacactt gcacccatttga 240
agacagctgc tatgcaacacc cttcttggtg tctactgttg gaggaggaag aatgtgctca 300
catgtcgaag agacacatcgg ctgtaatagg aatgtgcttc cccgggaatg tagaaacactt 360
agaggaacta aggtcatttt ttagtcttgc tagttcctact caaagaacct gcatcttttcc 420
agacacactc tgcagatgtgt ctccagagtt ccacaaagga gcatgtcagc attccttctca 480
caggagctag agatgtggtcg cttcacaagaa caacgcttac cctatacagc aacgctacaa 540
cacaataaat agaggaagaa gcattcttttt catgtggtggc ataaactacc cacctacccga 600	
tactgcagac aacaatctgt cccaaagacc gcaagctctg ccccaagcga 660
tataataagg accttcacac cgtgatagg gccaagcacc cttgtcataag gttcaggg 720
agaatgtgat tattattggt cggatggaa accaggtcag aactggcagg taagaatcaca 780
tgggaatccta atcgctccat ggtaggtgca cattcttcttc ggagagagcc agcggagaat 840
ccgcaagact gattaaaca gtttgtgctg tggtagtggc tggcataacag aaagaggggt 900
cctaaatct accttgctcat cccaaatgtc cagtaaatat gcatttggaag acgtcccaaa 960
atatgtgga gtaagagctc tcaaacctggc aaggggttctg aggatgtgca ctgctcagatc 1020
aagtagagga ctattttggg ccatagctgg attcataagag ggaggtggtt caggggtgtt 1080
cgctgttggtc ttagggtttcc acgtccaaac tgaatcaggg gttgtgtataag ctcagatag 1140
agactcaact caaagggcaa ttgacaaaat aacgtccaaa gtgaataata tagtgcataa 1200
aatgaacag caatatgaaa tatttgatca tgaatccagc gaggttgaaa atagactcaaa 1260
tatgatcaat aataagattg atgacaggat acaagacata tgggcatata acgctgaatt 1320
gctagtgctg cttgaaacc agaagaacact ctgatgagcat gatgcgaatt taaacaattct 1380
atataacaaa gtgaagaggg cactggtgttc caatgcaatg gaagatggga aaggatgttt 1440
cgagctatac cataaattgt atgtacatgtg ctaggagaca attcggaacg gacacccataa 1500
caggaggaag tataaaaggg aatacaagct caaagaagcag aaaaataagag ggggtaagct 1560
ggaatctgaa ggaaccttaca aatacctcac cattattttc actgt gcccct actctctctgt 1620
gattgcaatg gggttggctg cctctctgttt ctgggccatcg tccaatggat attgcaagt 1680
cacatttga 1690

<210>  10
<211> DNA
<212> Influenza virus
<400>  10
aatgaacag ataatagcag tgggtctttg tctctctact atggcagca 60
tatgctccct catcgagtatt gctatctttag caacgcactat gacactacat tccaagcaga 120
atatgaatgc caaatacctcg tagtgcctag tgaacacaatc ataataagaaa 180
ggaacataac agagatggtg catttggaat gtaactacctt agagaaggaat attttggctta 240
aagtagcag aatcagagat tggcataaac gacaatgctca aatcacaaggg ttgctctcttt 300
tctcacaagga caattcaatt aggctctcccg caggtggaga tattttgggtg acaagagaac 360
cttatgtatc gtgcgctctcttg gtaaatgtt atcaattttg acctggaagc ggaacaccatt 420
tggaagcaca acactcacaac ggcacacagc atgatagaaa ctctcatagaa acacactttaa 480
tgaatgtgatt ggggtgttcgg ttctattttgg caaaccacaac agttgtgccata gcgtggttcca 540
gtcaacagctg ccattgagggg aagcatgtgg tacattgttg tgtcactgag gatgcagaga 600
atgcacagggc tagcactatt tagatggaata taccctgttag cagattgtgt ctatgtggctta 660
aaaacatcct cgaacactcag ggtctgagaat gcctttggctg caatggaacc tggcagtag 720
ataatcagta tgggatgct cagtaacaggt gcgtctttctc ataatcatttt attagaggagg 780
ggaaatgtgc acacatgacc cccattggtg gcagttgtgga gaaatgtgttttctc 840
gttaaaaccgc atacaagaaaa ggttagattg tttcagagga caatggagag ggtcacaata 900
gggccgttct atataataat atggcaaaatt atagttattg tttcagttat gttgctcag 960
gactggtttg gcacacacaa agaagattag ataggtcttg cagcagcaac tcagagatc 1020
catacagga gagagggcc cccagagtaa aagggttgccc ctttgacaat gcagggacaca 1080
ttttgtaat aagaacacac acaaaaagtgg cgggtctcag ttatgagact ttcaaaattgtt 1140
tttggttttg gacactctgt aatcccaagt cacacataa tagacaaagtc atagtgacaa 1200
gtgaataactc gtctcgggtact ttctctgtttgc atggtctgcag ctggcagcata 1260
gggtttttta cgtggagtgg ataagaggaa gaccaagga gactagggtg tgtgggactt 1320
caaatagcat cattgtatct tgtggaacct caggtacctta tggaaacaggc tcatgcccgt 1380
atggggcgaa tatcaatttc atgcctatat aagccttcgc aathttag 1428

<210> 11
<211> 564
<212> PRT
<213> Influenza virus
<400> 11

Met Glu Lys Ile Val Leu Leu Phe Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15
Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30
Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45
Leu Glu Lys His Asn Gly Lys Leu Cys Asp Leu Asp Gly Val Lys 50 55 60
Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80
Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95
Glu Lys Ala Asn Pro Val Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn 100 105
Asp Tyr Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125
Lys Ile Gln Ile Ile Pro Lys Ser Ser Trp Ser Ser His Glu Ala Ser 130 135 140
Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Lys Ser Ser Phe Phe 145 150 155 160
Arg Asn Val Val Trp Leu Ile Lys Asn Ser Thr Tyr Pro Thr Ile 165 170 175
Lys Arg Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp 180 185 190
Gly Ile His His Pro Asn Ala Ala Gln Thr Lys Leu Tyr Gln 195 200 205
Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220

Page 10
Leu Val Pro Arg Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240

Arg Met Glu Phe Phe Trp Thr Ile Leu Lys Pro Asp Ala Ile Asn 245 250 255

Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270

Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly 275 280 285

Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser 290 295 300

Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320

Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335

Pro Gln Arg Glu Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile 340 345 350

Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His 355 360 365

Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln 370 375 380

Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys 385 390 395 400

Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Glu 405 410

Arg Arg Ile Glu Asn Leu Asn Lys Met Glu Asp Gly Phe Leu Asp 420 425 430

Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg 435 440 445

Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val 450 455 460

Arg Leu Gln Leu Arg Asp Ala Lys Glu Leu Gly Asn Gly Cys Phe 465 470 475 480

Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn 485 490 495

Page 11
Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg
500 505 510

Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Ile Tyr Gin Ile
515 520 525

Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala Leu Ala Ile Met
530 535 540

Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gin Cys
545 550 555 560

Arg Ile Cys Ile

<210> 12
<211> 449
<212> PRT
<213> Influenza virus

<400> 12
Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Val
1 5 10 15

Thr Gly Ile Val Ser Leu Met Leu Gin Ile Gly Asn Met Ile Ser Ile
20 25 30

Trp Val Ser His Ser Ile His Thr Gly Asn Gin His Gin Ser Glu Pro
35 40 45

Ile Ser Asn Thr Asn Phe Leu Thr Gln Lys Ala Val Ala Ser Val Lys
50 55 60

Leu Ala Gly Asn Ser Ser Leu Cys Pro Ile Asn Gly Trp Ala Val Tyr
65 70 75 80

Ser Lys Asp Asn Ser Ile Arg Ile Gly Ser Lys Gly Asp Val Phe Val
85 90 95

Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu Glu Cys Arg Thr Phe
100 105 110

Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn Gly Thr
115 120 125

Val Lys Asp Arg Ser Pro His Arg Thr Leu Met Ser Cys Pro Val Gly
130 135 140

Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp Ser
145 150 155 160

 Ala Ser Ala Cys His Asp Gly Thr Ser Trp Leu Thr Ile Gly Ile Ser
165 170 175

Page 12
Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys Tyr Asn Gly Ile Ile 180
Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Leu Arg Thr Gln Glu 195
Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr Val Met Thr Asp 210
215
Gly Pro Ser Asn Gly Glu Ala Ser His Lys Ile Phe Lys Met Glu Lys 225
230
235
240
Gly Lys Val Val Lys Ser Val Glu Leu Asp Ala Pro Asn Tyr His Tyr 245
250
255
Glu Glu Cys Ser Cys Tyr Pro Asn Ala Gly Glu Ile Thr Cys Val Cys 260
265
270
Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val Ser Phe Asn Glu 275
280
285
Asn Leu Glu Tyr Gln Ile Gly Tyr Ile Cys Ser Gly Val Phe Gly Asp 290
295
300
305
Asn Pro Arg Pro Asn Asp Gly Thr Gly Ser Cys Gly Pro Val Ser Ser 310
315
320
325
Asn Gly Ala Tyr Gly Val Lys Gly Phe Ser Phe Lys Tyr Gly Asn Gly 330
335
340
345
350
Val Trp Ile Gly Arg Thr Lys Ser Thr Asn Ser Arg Ser Gly Phe Glu 350
Met Ile Trp Asp Pro Asn Gly Trp Thr Glu Thr Asp Ser Ser Phe Ser 355
360
365
Val Lys Gln Asp Ile Val Ala Ile Thr Asp Trp Ser Gly Tyr Ser Gly 370
375
380
385
Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asp Cys Ile Arg Pro 390
395
400
Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Lys Glu Ser Thr Ile 405
410
415
Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val Asn Ser Asp Thr 420
425
430
435
Val Gly Trp Ser Thr Pro Asp Gly Ala Glu Leu Pro Phe Thr Ile Asp 440
445
Page 13
Lys

<210>  13
<211>  564
<212> PRT
<213> Influenza virus

<400>  13

Met Glu Lys Ile Val Leu Leu Phe Ala Ile Val Ser Leu Val Lys Ser  
  5       10        15

Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Ser Thr Glu Gln Val  
  20      25        30

Asp Thr Ile Met Glu Lys Val Thr Val Thr His Ala Gln Asp Ile  
  35      40        45

Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asp Gly Val Lys  
  50      55        60

Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn  
  65      70        75        80

Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val  
  85      90        95

Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn  
  100     105       110

Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu  
  115     120       125

Lys Ile Gln Ile Ile Pro Lys Asn Ser Trp Ser Ser His Glu Ala Ser  
  130     135       140

Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Lys Ser Ser Phe Phe  
  145     150       155       160

Arg Asn Val Val Trp Leu Ile Lys Asn Asn Ala Tyr Pro Thr Ile  
  165     170       175

Lys Arg Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp  
  180     185       190

Gly Ile His His Pro Asn Ala Ala Gln Thr Arg Leu Tyr Gln  
  195     200       205

Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg  
  210     215       220

Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Asn Gly
Arg Met Glu Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn
245 250 255
Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile
260 265 270
Val Lys Lys Gly Asp Ser Ala Ile Met Lys Ser Glu Leu Glu Tyr Gly
275 280 285
Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser
290 295 300 305
Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys
310 315 320
Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Ser
325 330 335
Pro Glu Arg Glu Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile
340 345 350
Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His
355 360 365
Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln
370 375 380
Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys
385 390 395 400
Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asp Leu Glu
405 410 415
Arg Arg Ile Glu Asn Leu Asn Lys Met Glu Asp Gly Phe Leu Asp
420 425 430
Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg
435 440 445
Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val
450 455 460
Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe
465 470 475 480
Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn
485 490 495
Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg
500 505 510
Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Thr Tyr Gln Ile 515 520
Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala Leu Ala Ile Met 530 535 540
Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys 545 550 555 560
Arg Ile Cys Ile

<211> 14
<212> PRT
<213> Influenza virus
<400> 14
Met Asn Pro Asn Gln Lys Ile Thr Thr Ile Gly Ser Ile Cys Met Val 1 5 10 15
Ile Gly Ile Val Ser Leu Met Leu Gln Ile Gly Asn Ile Ile Ser Ile 20 25 30
Trp Val Ser His Ser Ile Gln Thr Gly Asn Gln His Gln Ala Glu Pro 35 40 45
Cys Asn Gln Ser Ile Ile Thr Tyr Glu Asn Thr Trp Val Asn Gln 50 55 60
Thr Tyr Val Asn Ile Ser Asn Thr Asn Phe Leu Thr Glu Lys Ala Val 65 70 75 80
Ala Ser Val Thr Leu Ala Gly Asn Ser Ser Leu Cys Pro Ile Ser Gly 85 90 95
Trp Ala Val Tyr Ser Lys Asp Asn Gly Ile Arg Ile Gly Ser Lys Gly 100 105 110
Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu Glu 115 120 125
Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His 130 135 140
Ser Asn Gly Thr Val Lys Asp Arg Ser Pro His Arg Thr Leu Met Ser 145 150 155 160
Cys Pro Val Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser 165 170 175
Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Ser Trp Leu Thr 180 185 190
Ile Gly Ile Ser Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys Tyr 195 200 205
Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Met 210 215 220
Arg Thr Glu Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr 225 230 235 240
Val MetThr Asp Gly Pro Ser Asn Gly Gln Ala Ser Tyr Lys Ile Phe 245 250 255
Arg Ile Glu Lys Gly Lys Val Val Lys Ser Ala Glu Leu Asn Ala Pro 260 265 270
Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ala Gly Glu Ile 275 280 285
Thr Cys Val Cys Arg Asp Thr Cys Gly Thr Ser Asn Arg Pro Trp Val 290 295 300
Ser Phe Asn Gln Asn Leu Glu Tyr Arg Ile Gly Tyr Ile Cys Ser Gly 305 310 315 320
Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Gly Thr Gly Ser Cys Gly 325 330 335
Pro Val Ser Pro Lys Gly Ala Tyr Gly Ile Lys Gly Phe Ser Phe Lys 340 345 350
Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Thr Asn Ser Arg 355 360 365
Ser Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp 370 375 380
Ser Asn Phe Ser Val Lys Gln Asp Ile Val Ala Ile Thr Asp Trp Ser 385 390 395 400
Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asp 405 410 415
Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Lys 420 425 430
Glu Ser Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val 435 440 445
Asn Ser Asp Thr Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro
Leu Val Pro Glu Ile Ala Thr Arg Pro Lys Val Asn Gly Gln Ser Gly
225 230 235 240

Arg Met Glu Phe Phe Trp Thr Ile Leu Lys Pro Asn Ala Ile Asn
245 250 255

Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile
260 265 270

Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly
275 280 285

Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser
290 295 300

Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys
305 310 315 320

Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Thr
325 330 335

Pro Gln Arg Glu Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile
340 345 350

Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His
355 360 365

Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Glu Ser Thr Gln
370 375 380

Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asn Lys
385 390 395 400

Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Gly
405 410 415

Arg Arg Ile Glu Asn Leu Asn Lys Met Glu Asp Gly Phe Leu Asp
420 425 430

Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg
435 440 445

Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val
450 455 460

Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe
465 470 475 480

Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Lys Asn
485 490 495

Page 19
Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Asn Arg
500
505
510

Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Met Gly Thr Tyr Gln Ile
515
520
525

Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala Leu Ala Ile Met
530
535
540

Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys
545
550
555
560

Arg Ile Cys Ile

<210> 16
<211> 450
<212> PRT
<213> Influenza virus

<400> 16

Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Val
1
5
10
15

Val Gly Ile Ile Ser Leu Met Leu Gln Ile Gly Asn Thr Ile Ser Val
20
25
30

Trp Val Ser His Ile Ile Lys Thr Trp His Pro Asn Gln Pro Glu Pro
35
40
45

Cys Asn Gln Ser Ile Asn Phe Tyr Thr Glu Gln Ala Ala Ala Ser Val
50
55
60

Thr Leu Ala Gly Asn Ser Ser Leu Cys Pro Ile Ser Gly Trp Ala Ile
65
70
75
80

Tyr Ser Lys Asp Ser Ser Ile Arg Ile Gly Ser Lys Gly Asp Val Phe
85
90
95

Val Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu Glu Cys Arg Thr
100
105
110

Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn Gly
115
120
125

Thr Val Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser Cys Pro Val
130
135
140

Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp
145
150
155
160

Ser Ala Ser Ala Cys His Asp Gly Ile Ser Trp Leu Thr Ile Gly Ile
165
170
175
Page 20
Ser Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys Tyr Asn Gly Ile
180 185

Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Thr Leu Arg Thr Gln
195 200 205

Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr Val Met Thr
210 215 220

Asp Gly Pro Ser Asn Glu Gln Ala Ser Tyr Lys Ile Phe Lys Ile Glu
225 230 235 240

Lys Gly Arg Val Val Lys Ser Val Glu Leu Asn Ala Pro Asn Tyr His
245 250 255

Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ala Gly Glu Ile Thr Cys Val
260 265 270

Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val Ser Phe Asn
275 280 285

Gln Asn Leu Glu Tyr Gln Ile Gly Tyr Ile Cys Ser Gly Val Phe Gly
290 295 300

Asp Ser Pro Arg Pro Asn Asp Gly Thr Gly Ser Cys Gly Pro Val Ser
305 310 315 320

Leu Asn Gly Ala Tyr Gly Val Lys Gly Phe Ser Phe Lys Tyr Gly Asn
325 330 335

Gly Val Trp Ile Gly Arg Thr Lys Ser Thr Ser Ser Arg Ser Gly Phe
340 345 350

Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Glu Thr Asp Ser Ser Phe
355 360 365

Ser Leu Lys Gln Asp Ile Ile Ala Ile Thr Asp Trp Ser Gly Tyr Ser
370 375 380

Gly Ser Phe Ile Gln His Pro Glu Leu Thr Gly Leu Asn Cys Met Arg
385 390 395 400

Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Lys Glu Lys Thr
405 410 415

Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val Asn Ser Asp
420 425 430

Thr Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro Tyr Thr Ile
435 440 445
<table>
<thead>
<tr>
<th>Asp Lys</th>
<th>450</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met Glu Lys Ile Val Leu Leu Leu Ala Thr Val Ser Leu Val Lys Ser</td>
<td>1 5 10 15</td>
</tr>
<tr>
<td>Asp Glu Ile Cys Ile Gly Tyr His Ala Asn Ser Thr Glu Gln Val</td>
<td>20 25 30</td>
</tr>
<tr>
<td>Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile</td>
<td>35 40 45</td>
</tr>
<tr>
<td>Leu Glu Arg Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys</td>
<td>50 55 60</td>
</tr>
<tr>
<td>Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn</td>
<td>65 70 75 80</td>
</tr>
<tr>
<td>Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val</td>
<td>85 90 95</td>
</tr>
<tr>
<td>Glu Lys Ala Ser Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn</td>
<td>100 105 110</td>
</tr>
<tr>
<td>Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu</td>
<td>115 120 125</td>
</tr>
<tr>
<td>Lys Ile Gln Ile Ile Pro Lys Ser Ser Trp Ser Asn His Asp Ala Ser</td>
<td>130 135 140</td>
</tr>
<tr>
<td>Ser Gly Val Ser Ser Ala Cys Pro Tyr Leu Gly Arg Ser Ser Phe Phe</td>
<td>145 150 155 160</td>
</tr>
<tr>
<td>Arg Asn Val Val Trp Leu Ile Lys Asn Ser Ser Tyr Pro Thr Ile</td>
<td>165 170 175</td>
</tr>
<tr>
<td>Lys Arg Ser Tyr Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp</td>
<td>180 185 190</td>
</tr>
<tr>
<td>Gly Ile His His Pro Asn Ala Ala Glu Gln Thr Arg Leu Tyr Gln</td>
<td>195 200 205</td>
</tr>
<tr>
<td>Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg</td>
<td>210 215 220</td>
</tr>
<tr>
<td>Leu Val Ser Glu Ile Ala Thr Arg Pro Lys Val Asn Gly Gln Ser Gly</td>
<td>Page 22</td>
</tr>
</tbody>
</table>
Arg Met Glu Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245

Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260

Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly 275

Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser 290

Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305

Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Thr 325

Pro Gln Arg Glu Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile 340

Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His 355

Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Glu Ser Thr Gln 370

Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asn Lys 385

Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asp Leu Glu 405

Arg Arg Ile Glu Asn Leu Asn Lys Gly Met Glu Asp Gly Phe Leu Asp 420

Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg 435

Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val 450

Arg Leu Gln Leu Arg Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe 465

Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Lys Asn 485

Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Asn Arg 500
Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Met Gly Thr Tyr Gln Ile 515
Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala Leu Ala Ile Met 530
Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys 545
Arg Ile Cys Ile 560

<210> 18
<211> 450
<212> PRT
<213> Influenza virus
<400> 18

Met Asn Pro Asn Gln Lys Ile Ile Ile Gln Ser Ile Cys Met Val 1
Val Gly Ile Ile Ser Leu Met Leu Gln Ile Gly Thr Ile Ser Val 20
25
Trp Val Ser His Ile Ile Lys Thr Trp His Pro Asn Gln Pro Glu Pro 35
40
45
Cys Asn Gln Ser Ile Asn Phe Tyr Thr Glu Gln Ala Ala Ala Ser Val 50
55
60
Thr Leu Ala Gly Asn Ser Ser Leu Cys Pro Ile Ser Gly Trp Ala Ile 65
70
75
80
Tyr Ser Lys Asp Asn Ser Ile Arg Ile Gly Ser Lys Gly Asp Val Phe 85
90
95
Val Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu Glu Cys Arg Thr 100
105
110
Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn Gly 115
120
125
Thr Val Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser Cys Pro Val 130
135
140
Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp 145
150
155
160
Ser Ala Ser Ala Cys His Asp Gly Ile Ser Trp Leu Thr Ile Gly Ile 165
170
175
<table>
<thead>
<tr>
<th>Ser</th>
<th>Gly</th>
<th>Pro</th>
<th>Asp</th>
<th>Asn</th>
<th>Gly</th>
<th>Ala</th>
<th>Val</th>
<th>Ala</th>
<th>Val</th>
<th>Leu</th>
<th>Lys</th>
<th>Tyr</th>
<th>Asn</th>
<th>Gly</th>
<th>Ile</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Thr</td>
<td>Asp</td>
<td>Thr</td>
<td>Ile</td>
<td>Lys</td>
<td>Ser</td>
<td>Trp</td>
<td>Arg</td>
<td>Asn</td>
<td>Thr</td>
<td>Leu</td>
<td>Arg</td>
<td>Thr</td>
<td>Gln</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu</td>
<td>Ser</td>
<td>Glu</td>
<td>Cys</td>
<td>Ala</td>
<td>Cys</td>
<td>Val</td>
<td>Asn</td>
<td>Gly</td>
<td>Ser</td>
<td>Cys</td>
<td>Phe</td>
<td>Thr</td>
<td>Val</td>
<td>Met</td>
<td>Thr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td>Gly</td>
<td>Pro</td>
<td>Ser</td>
<td>Asn</td>
<td>Glu</td>
<td>Gln</td>
<td>Ala</td>
<td>Ser</td>
<td>Tyr</td>
<td>Lys</td>
<td>Ile</td>
<td>Phe</td>
<td>Lys</td>
<td>Ile</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lys</td>
<td>Gly</td>
<td>Arg</td>
<td>Val</td>
<td>Val</td>
<td>Lys</td>
<td>Ser</td>
<td>Val</td>
<td>Glu</td>
<td>Leu</td>
<td>Asn</td>
<td>Ala</td>
<td>Pro</td>
<td>Asn</td>
<td>Tyr</td>
<td>His</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyr</td>
<td>Glu</td>
<td>Glu</td>
<td>Cys</td>
<td>Ser</td>
<td>Cys</td>
<td>Tyr</td>
<td>Pro</td>
<td>Asp</td>
<td>Ala</td>
<td>Gly</td>
<td>Glu</td>
<td>Ile</td>
<td>Thr</td>
<td>Cys</td>
<td>Val</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cys</td>
<td>Arg</td>
<td>Asp</td>
<td>Asn</td>
<td>Trp</td>
<td>His</td>
<td>Gly</td>
<td>Ser</td>
<td>Asn</td>
<td>Arg</td>
<td>Pro</td>
<td>Trp</td>
<td>Val</td>
<td>Ser</td>
<td>Phe</td>
<td>Asn</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Asn</td>
<td>Leu</td>
<td>Glu</td>
<td>Tyr</td>
<td>Gln</td>
<td>Ile</td>
<td>Gly</td>
<td>Tyr</td>
<td>Ile</td>
<td>Cys</td>
<td>Ser</td>
<td>Gly</td>
<td>Val</td>
<td>Phe</td>
<td>Gly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td>Ser</td>
<td>Pro</td>
<td>Arg</td>
<td>Pro</td>
<td>Asn</td>
<td>Asp</td>
<td>Gly</td>
<td>Thr</td>
<td>Gly</td>
<td>Ser</td>
<td>Cys</td>
<td>Gly</td>
<td>Pro</td>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Asn</td>
<td>Gly</td>
<td>Ala</td>
<td>Tyr</td>
<td>Gly</td>
<td>Val</td>
<td>Lys</td>
<td>Gly</td>
<td>Phe</td>
<td>Ser</td>
<td>Phe</td>
<td>Lys</td>
<td>Tyr</td>
<td>Gly</td>
<td>Asn</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly</td>
<td>Val</td>
<td>Trp</td>
<td>Ile</td>
<td>Gly</td>
<td>Arg</td>
<td>Thr</td>
<td>Lys</td>
<td>Ser</td>
<td>Thr</td>
<td>Ser</td>
<td>Arg</td>
<td>Ser</td>
<td>Gly</td>
<td>Phe</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu</td>
<td>Met</td>
<td>Ile</td>
<td>Trp</td>
<td>Asp</td>
<td>Pro</td>
<td>Asn</td>
<td>Gly</td>
<td>Trp</td>
<td>Thr</td>
<td>Glu</td>
<td>Thr</td>
<td>Asp</td>
<td>Ser</td>
<td>Ser</td>
<td>Phe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Leu</td>
<td>Lys</td>
<td>Gln</td>
<td>Asp</td>
<td>Ile</td>
<td>Ala</td>
<td>Ile</td>
<td>Thr</td>
<td>Asp</td>
<td>Trp</td>
<td>Ser</td>
<td>Gly</td>
<td>Tyr</td>
<td>Ser</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly</td>
<td>Ser</td>
<td>Phe</td>
<td>Ile</td>
<td>Gln</td>
<td>His</td>
<td>Pro</td>
<td>Glu</td>
<td>Leu</td>
<td>Thr</td>
<td>Gly</td>
<td>Leu</td>
<td>Asn</td>
<td>Cys</td>
<td>Met</td>
<td>Arg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro</td>
<td>Cys</td>
<td>Phe</td>
<td>Trp</td>
<td>Val</td>
<td>Glu</td>
<td>Leu</td>
<td>Ile</td>
<td>Arg</td>
<td>Gly</td>
<td>Arg</td>
<td>Pro</td>
<td>Lys</td>
<td>Glu</td>
<td>Lys</td>
<td>Thr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Trp</td>
<td>Thr</td>
<td>Ser</td>
<td>Gly</td>
<td>Ser</td>
<td>Ser</td>
<td>Ile</td>
<td>Ser</td>
<td>Phe</td>
<td>Cys</td>
<td>Gly</td>
<td>Val</td>
<td>Asn</td>
<td>Ser</td>
<td>Asp</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
<td>Gly</td>
<td>Trp</td>
<td>Ser</td>
<td>Trp</td>
<td>Pro</td>
<td>Asp</td>
<td>Gly</td>
<td>Ala</td>
<td>Glu</td>
<td>Leu</td>
<td>Pro</td>
<td>Tyr</td>
<td>Thr</td>
<td>Ile</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td>Lys</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Met Glu Ala Ile Pro Leu Ile Thr Ile Leu Leu Val Val Thr Ala Ser</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Asn Ala Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Thr Val Asp Thr Leu Thr Glu Asn Asn Val Pro Val Thr His Ala Lys</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Asn Leu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Gly Arg Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Gly Asn Pro Ser Cys Asp Leu Leu Leu Gly Gly Arg Glu Trp Ser Tyr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Ile Val Glu Arg Pro Ser Ala Val Asn Gly Met Cys Tyr Pro Gly Asn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>Val Glu Asn Leu Glu Glu Leu Arg Ser Phe Phe Ser Ser Ala Ser Ser</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>Tyr Glu Asp Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Ser Tyr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Thr Leu Thr Gln Lys Asn Ala Tyr Pro Ile Gln Asp Ala Glu Tyr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>Thr Asn Asn Arg Gly Lys Ser Ile Leu Phe Met Trp Gly Ile Asn His</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>Pro Pro Thr Asp Thr Ala Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>125</td>
<td>Thr Thr Ser Val Ala Thr Glu Asp Ile Asn Arg Thr Phe Lys Pro Val</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Gln Gly Arg Ile Asp Tyr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>Pro Pro Thr Asp Thr Ala Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>Thr Thr Ser Val Ala Thr Glu Asp Ile Asn Arg Thr Phe Lys Pro Val</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tyr Trp Ser Val Leu Lys Pro Gly Glu Thr Leu Arg Val Arg Ser Asn
245 250 255
Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser
260 265 270
His Gly Arg Ile Leu Lys Thr Asp Leu Asn Ser Gly Ser Cys Val Val
275 280 285
Gln Cys Glu Thr Glu Arg Gly Gly Leu Asn Thr Thr Leu Pro Phe His
290 295 300
Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Pro Lys Tyr Val Gly Val
305 310 315 320
Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ala Arg Ser
325 330 335
Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp
340 345 350
Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asp Gln
355 360 365
Gly Val Gly Ile Ala Ala Asp Arg Asp Ser Thr Gln Arg Ala Ile Asp
370 375 380
Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln
385 390 395 400
Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Val Glu Asn Arg Leu Asn
405 410 415
Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Gln Asp Ile Trp Ala Tyr
420 425 430
Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Glu Thr Leu Leu Asp Glu
435 440 445
His Asp Ala Asn Val Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu
450 455 460
Gly Ser Asn Ala Met Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His
465 470 475 480
Lys Cys Asp Asp Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn
485 490 495
Arg Arg Lys Tyr Lys Glu Glu Ser Arg Leu Glu Arg Glu Cys Leu Ile Glu
500 505 510
Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Leu Thr Thr Lys Tyr
515 520 525
Ser Thr Val Ala Ser Ser Leu Val Ile Ala Met Gly Phe Ala Ala Phe
530 535 540
Leu Phe Trp Ala Met Ser Asn Gly Ser Cys Arg Cys Asn Ile
545 550 555

<210> 20
<211> 469
<212> PRT
<213> Influenza virus
<400> 20
Met Asn Pro Asn Gln Lys Ile Ile Ala Ile Gly Ser Val Ser Leu Thr
1 5 10 15
Ile Ala Thr Ile Cys Leu Leu Met Gln Ile Ala Ile Leu Ala Thr Thr
20 25 30
Met Thr Leu His Phe Lys Gln Asn Glu Cys Ile Asn Ser Ser Asn Asn
35 40 45
Gln Val Val Pro Cys Glu Pro Ile Ile Ile Ile Gly Arg Asn Ile Thr Glu
50 55 60
Ile Val His Leu Asn Ser Thr Thr Leu Glu Lys Gly Ile Cys Pro Lys
65 70 75 80
Val Ala Asp Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gln Ile Thr Gly
85 90 95
Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly
100 105 110
Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Gly Leu Gly Lys
115 120 125
Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Glu Asn Lys His
130 135 140
Ser Asn Gly Thr Ala His Asp Arg Thr Pro His Arg Thr Leu Leu Met
145 150 155 160
Asn Glu Leu Gly Val Pro Phe His Leu Ala Thr Lys Gln Val Cys Ile
165 170 175
Ala Trp Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val
180 185 190
Cys Val Thr Gly Asp Asp Arg Asn Ala Thr Ala Ser Ile Ile Tyr Asp
195 200 205
Page 28
Gly Ile Leu Val Asp Ser Ile Gly Ser Trp Ser Lys Asn Ile Leu Arg 210
Thr Glu Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Ala Val Val 225
Met Thr Asp Gly Ser Ala Ser Gly Arg Ala Asp Thr Arg Ile Leu Phe 245
Ile Arg Glu Gly Lys Ile Ala His Ile Ser Pro Leu Ser Gly Ser Ala 260
Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Glu Val Arg 275
Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Val Leu Tyr 290
Ile Asn Met Ala Asn Tyr Ser Ile Asp Ser Ser Tyr Val Cys Ser Gly 305
Leu Val Gly Asp Thr Pro Arg Asn Asp Asp Arg Ser Ser Ser Ser Asn 325
Cys Arg Asp Pro Asn Asn Glu Arg Gly Ala Pro Gly Val Lys Gly Trp 340
Ala Phe Asp Asn Gly Asn Asp Ile Trp Met Gly Arg Thr Ile Lys Lys 355
Asp Ser Arg Ser Gly Tyr Glu Thr Phe Arg Val Ile Gly Gly Trp Thr 370
Thr Ala Asn Ser Lys Ser Glu Ile Asn Arg Gln Val Ile Val Asp Ser 385
Asp Asn Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser 390
Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Pro Lys 405
Glu Thr Arg Val Trp Trp Thr Ser Asn Ser Ile Ile Val Phe Cys Gly 420
Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asn Ile 435
Asn Phe Met Pro Ile 465